Automatic measurement of lesions on medical images

The present invention relates to a method for assessing the presence and/or the severity of a lesion in an organ or tissue of a subject through automated analysis of at least one image of said organ or tissue, wherein said organ or tissue is preferably a liver organ or liver tissue, comprising the calculation of a score combining descriptors of said image, wherein said method comprises the steps of:

a. measuring on said at least one image at least two descriptors of said at least one image;
b. mathematically combining said at least two descriptors in a score; and
c. assessing the presence and/or the severity of a lesion in the organ or tissue based on the value of the score calculated at step (b).
The present invention relates to the analysis of medical images. More specifically, the present invention relates to an automatic method for assessing the presence and/or the severity of lesions in an organ, based on the computerized analysis of a medical image of this organ.

BACKGROUND OF INVENTION

All chronic liver diseases (causes: viral, alcohol, diabetes...) are characterized by the development of liver lesions and the development of liver fibrosis. This liver fibrosis induces liver architecture modifications which are the source of major complications responsible for increased mortality. Fibrosis is progressive and usually reversible.

Quantification of hepatic fibrosis is important to determine the severity of liver disease, its prognosis and treatment indication. The quantification reference of hepatic fibrosis is a microscopical examination by an expert liver pathologist of a liver specimen usually obtained by liver biopsy (LB). Liver fibrosis is staged according to LB in semi quantitative reference system of pathologists, i.e. for example in the field of hepatology, the METAVIR fibrosis score with 5 classes (F0: no fibrosis; F1: portal fibrosis without septa; F2: portal fibrosis with rare septa; F3: numerous septa without cirrhosis; F4: cirrhosis) and the Ishak staging system with 7 classes based on portal and septal fibrosis and the degree of completeness for cirrhosis.

Currently the conventional reading of LB has limits. Indeed, these semi-quantitative scoring systems of fibrosis are limited by poor inter- or intra-observer reproducibility between pathologists. The most important issue regarding the classification system by pathologists is that it is subjective. The limit of the poor reproducibility can be partially circumvented with the LB reading by an expert. However, a recent study showed that single experts did not reach excellent reproducibility whereas an expert panel seems to be the best reading reference (Boursier et al, BMC Gastroenterol, 2011, 11:132).

Thus, the challenging issue in pathology is to work with expert centers, with the probable risk of saturation. In addition, there is a rarefaction or increasing unavailability of pathologists.

There is thus a need for an image analysis method which is automated and thus allows the effective assessment of the presence and/or the severity of a lesion in an organ, such as, for example, the presence of liver fibrosis.

Medical images analysis methods are known in the prior art.

For example, the US patent application US 2012/226709 describes an automated method for identifying prostate tissue samples in a database that are closest to a test prostate sample, in order to aid pathologists in diagnosing prostate cancer.

Moreover, the International patent application WO 2006/020627 describes a method for automated diagnosis of a disease, specifically of cancer, based on morphometric data extracted from tissue images by a computer. Examples of morphometric data include fractal dimension data, wavelet data and color channel histogram data.

In the field of hepatology, several methods of fibrosis morphometric measurements to describe its quantitative characteristics have been described: among different patterns, the area of fibrosis is the main characteristic. Fractal dimension of fibrosis, the perimeter and the size of collagenous elements were also described. For example, the European patent EP 2 021 933 describes a computerized in vitro diagnostic method for liver diseases, comprising measuring in a liver biopsy image, inflammation parameters (such as, for example, area of inflammatory tissue or the percentage of biopsy sample surface occupied by the inflammatory tissue) or fibrosis parameters (such as, for example, fractal dimension or corrected area of the fibrotic tissue).

However, these published techniques give quantitative information but are not well correlated with the diagnostic reference system of pathologists, i.e. for example in the field of hepatology, the METAVIR fibrosis score with 5 classes (F0: no fibrosis; F1: portal fibrosis without septa; F2: portal fibrosis with rare septa; F3: numerous septa without cirrhosis; F4: cirrhosis) and the Ishak staging system with 7 classes based on portal and septal fibrosis and the degree of completeness for cirrhosis.

At the difference of the current image analysis methods of the prior art, the Inventors herein developed a diagnostic method able to determine the fibrosis course that is well correlated with the expert’s classification. So, they developed an automated measurement of many new morphometric patterns which describe quantitatively the information needed by pathologists when they make the METAVIR fibrosis (F) staging. All these measures may thus be used as a complement to classical optical diagnosis as required by the local conditions of clinical practice. Moreover, the method of the invention comprises the mathematical combination of these data in a score, thus allowing determining, with an automated measure and calculation the METAVIR stage or diagnosing clinically significant fibrosis (CSF, METAVIR F≥2) and cirrhosis (METAVIR F4), with excellent accuracy and reproducibility.
SUMMARY

The present invention thus relates to a method for assessing the presence and/or the severity of a lesion in an organ or tissue of a subject through automated analysis of at least one image of said organ or tissue, wherein said organ or tissue is preferably a liver organ or liver tissue, comprising the calculation of a score combining descriptors of said image, wherein said method comprises the steps of:

a. measuring on said at least one image at least two, descriptors of said at least one image;
b. mathematically combining said at least two descriptors in a score; and
c. assessing the presence and/or the severity of a lesion in the organ or tissue based on the value of the score calculated at step (b).

In one embodiment, said method is computerized.

In one embodiment, the at least two descriptors are selected from the list comprising fractal dimension of the edges of the organ or fragment thereof, linearity percentage of the edges, nodularity of the curved and irregular edges of the organ, angularity, length of the organ or fragment thereof, length of a biopsy, such as, for example, length of a liver biopsy, length of numeric specimen, height of the organ, perimeter of the organ or fragment thereof, mean and total native perimeter of the organ, smoothed perimeter of the organ, ratio between the native and smoothed perimeters, largest perimeter of the organ, indentation of the organ, area of the organ or fragment thereof, granularity percentage, fragmentation, mean intensity of the image on the red component, mean intensity of the image on the green component, mean intensity of the image on the blue component, area of fibrosis, fractal dimension of fibrosis, mean of percentage of fibrosis around areas, number of nodules, number of nodules with more than 30% of fibrosis around, area of steatosis, relative area of steatosis, fractal dimension of steatosis, area of porto-septal fibrosis, fractal dimension of porto-septal fibrosis, area of peri-sinusoidal fibrosis, fractal dimension of peri-sinusoidal fibrosis, area of lobular peri-sinusoidal fibrosis, ratio of peri-sinusoidal fibrosis among the whole fibrosis, luminosity of fibrosis staining in the red, green and/or blue components, luminosity of the parenchyma staining in the red, green and/or blue components, luminosity contrast between fibrosis and parenchyma, luminosity contrast between fibrosis and the organ or fragment thereof, area of stellar fibrosis among the total surface of the LB specimen, area of stellar fibrosis among the surface of porto-septal regions, area of stellar fibrosis among the surface of lobular regions, number of porto-septal regions; mean area of stellar fibrosis, mean area of porto-septal regions, number of bridges, ratio of bridges among the porto-septal areas, area of fibrosis in the bridges, bridges thickness, bridges perimeter, bridges surface, portal distance, organ fat ratio, abdominal fat ratio, hypertrophy of liver segment I, surface of the segment I, width of the liver segment IV, ratio between segment I and segment IV dimensions, furrow thickness, surface of the furrow, internal nodularity in the liver, diameter of the portal vein, heterogeneity of the density intensity, fractal organization of the organ.

In one embodiment, the at least one image is a histological section image, more preferably an image of a histological section from a biopsy sample of said organ or tissue; or an image of the entire organ or tissue, more preferably said image is non-invasively recovered from a living organism.

In one embodiment, the method of the invention comprises recovering:

- at least one histological section image, more preferably an image of a histological section from a biopsy sample of said organ or tissue; and
- at least one image of the entire organ or tissue, more preferably said image is non-invasively recovered from a living organism.

In one embodiment, the at least one image is obtained by an optical technique, preferably microscopic physical imaging, such as, for example electron microscopy, second harmonic generation (SHG), multiphoton imaging, coherent anti-Stokes Raman scattering - CARS), two-photon excitation fluorescence (TPEF), diffuse optical imaging or event-related optical signal.

In one embodiment, the at least one image is obtained by a non-optical technique, preferably selected from the group comprising radiography, such as, for example, X-ray, ultrasonography, computerized scanner, magnetic resonance imaging (MRI), functional magnetic resonance imaging, tomography, computed axial tomography, proton emission tomography (PET) or single photon emission computed tomography; and nuclear medicine, such as, for example, scintigraphy; photoacoustic methods; thermal methods; and magnetonecephalography.

In one embodiment, the mathematical combination is a combination using a mathematical function, preferably a multivariate analysis, more preferably a multivariate analysis selected from the list comprising binary logistic regression, linear discriminant analysis or multivariate analysis.

In one embodiment, the lesion is a fibrosis.
intestine, pancreas, bone marrow, muscle, joints and soft tissue such as, for example, soft tissue of the mediastinum or soft tissue of the retroperitoneum.

[0024] In one embodiment, the lesion is a liver fibrosis, preferably a portal fibrosis or a peri-sinusoidal fibrosis.

[0025] In one embodiment, the score obtained in step (c) is a diagnostic score indicative of the presence and/or of the severity of a disease, preferably of cirrhosis or of clinically significant fibrosis, more preferably of clinically significant fibrosis (septal fibrosis).

[0026] In one embodiment, the score obtained in step (c) is a diagnostic score indicative of the presence and/or of the severity of NASH, preferably definitive or borderline and definitive NASH.

[0027] In one embodiment, the score obtained in step (c) is a diagnostic score indicative of the presence and/or of the severity of NASH, preferably definitive or borderline and definitive NASH.

[0028] In one embodiment, the method of the invention further comprises measuring at least one non-invasive test marker, and optionally mathematically combining said at least one non-invasive test marker with the at least two descriptors in a score.

[0029] Another object of the present invention is a descriptor selected from the group comprising fractal dimension of the edges of the organ or fragment thereof, linearity percentage of the edges, nodularity of the curved and irregular edges of the organ, angularity, length of the organ or fragment thereof, length of a biopsy, such as, for example, length of a liver biopsy, length of numeric specimen (N_LENGTH), height of the organ, diameter of the liver segment I, width of the liver segment IV, ratio between segment I and segment IV dimensions, furrow thickness, surface of the furrow I, internal nodularity in the liver, diameter of the portal vein, heterogeneity of the density intensity, fractal organization of the organ.

DEFINITIONS

[0030] In the present invention, the following terms have the following meanings:

- "Descriptor" refers to any computer-generated data associated with or derived from an image of an organ or tissue. Examples of computer-generated data include, but are not limited to, data regarding structural properties of the organ or tissue (such as, for example, its length), spectral properties of the organ or tissue image (such as, for example, contrast or luminosity), fractal properties of the organ or tissue, shape of the organ or tissue, and other image data transforms.

- "Lesion": refers to any abnormality in a tissue or an organ of an organism. In one embodiment of the invention, a lesion is caused by a disease, and may consequently be referred as a "pathological lesion".

- "Fibrosis" refers to a lesion, preferably a pathological lesion, made of scaring tissue including, but not limited to, fibrillar proteins or glycoproteins, such as, for example, collagens or proteoglycans.

- "Steatosis" refers to a lesion, preferably a pathological lesion, resulting from the accumulation of lipids, usually triglycerides within vacuoles of cells.

- "Inflammation" refers to a stereotyped response of an organism to harmful stimuli, involved in innate immunity. Classical signs of inflammation that may be visualized include, but are not limited to, redness, swelling, and cell infiltrates.
- "Score" refers to any digit value obtained by a test for assessing the presence and/or severity of a lesion, involving the mathematical combination of at least one descriptor and/or non-invasive tests marker. In one embodiment, a score is a digit value, preferably an unbound digit value. In another embodiment, a score is a bound digit value, obtained by a mathematical function such as, for example, a logit function. Preferably, a score ranges from 0 to 1. In one embodiment, the descriptors and/or non-invasive tests markers mathematically combined in a score are independent, i.e. give each an information that is different and not linked to the information given by the others.

- "Accuracy" of a method for assessing the presence and/or the severity of a lesion in an organ refers to the proportion of correctly assessed subjects by the method. In one embodiment where the method of the invention implies a binary diagnostic, the accuracy of the method may be assessed by measuring the percentage of correctly diagnosed or classified subjects, and/or by measuring the AUROC (area under the receiver operator characteristic), based on sensitivity and specificity, of the method. In another embodiment where the method is for predicting the class of a classification to which a subject belongs, the accuracy of the method may be assessed by measuring the agreement with the reference, such as the weighted kappa index discarding chance expected agreement.

- "About" preceding a figure means plus or less 10% of the value of said figure.

DETAILED DESCRIPTION

[0031] The present invention relates to a method for assessing the presence and/or the severity of a lesion in a tissue (preferably a liver tissue) or an organ (preferably liver) of a subject through automated analysis of at least one image of said organ or tissue, comprising the calculation of a score combining descriptor(s) of said image, wherein said method comprises the steps of:

a. measuring on said at least one image at least one descriptor of said at least one image;
b. mathematically combining said at least one descriptor in a score; and
c. assessing the presence and/or the severity of a lesion in the organ or tissue based on the value of the score calculated at step (b).

[0032] In one embodiment of the invention, at least 2, 3, preferably at least 4, 5, 6, 7 or 8 descriptors are measured at step (b) and/or mathematically combined at step (c).

[0033] In one embodiment, the method of the present invention may thus also be defined as an automated morphometry method, wherein morphometry refers to the quantitative measurement of forms, shape or other characteristics of organs or tissues.

[0034] In one embodiment of the invention, the method is computerized, which means that the image analysis leading to a score is carried out by a computer, without the intervention of a human operator.

[0035] In another embodiment, the method is essentially computerized, which means that a human operator may intervene in some steps, such as, for example, for recovering the image or for removing artefacts on the image of the organ to be analyzed. However, the image analysis per se, i.e. the measurement of the at least two descriptors and the mathematical combination thereof is computerized.

[0036] The present invention thus also relates to a software for implementing the method of the invention.

[0037] In one embodiment of the invention, the at least one image is an electronic or digital image.

[0038] In a first embodiment, the electronic or digital image is recovered directly after the medical examination. In a second embodiment, the electronic or digital image is a scanned image of the medical examination result.

[0039] In a first embodiment, the image is a two-dimensional image, such as, for example, a histological section image, preferably an image of a histological section of a biopsy sample from said organ or tissue.

[0040] In a second embodiment, the image is a three-dimensional image, such as, for example, an image of an entire organism, organ or tissue, preferably non-invasively recovered from a living organism.

[0041] In one embodiment of the invention, the two-dimensional image is an image from a biopsy sample, such as, for example, an image of a histological section of a biopsy. As used herein, the term "histological section" refers to a thin slice of tissue applied to a microscopic slide. In another embodiment, the two-dimensional image corresponds to a slice of a three-dimensional image, such as, for example, a slice of an image of an entire organism, organ or tissue non-invasively recovered from a living organism.

[0042] In one embodiment of the invention, the biopsy sample is transformed before the method of the invention is carried out.

[0043] Examples of transformations that may be applied to the biopsy sample include, but are not limited to, gross cutting of the biopsy material; fixation, such as, for example, by the fixed tissue method with paraffin, fixation with formalin or by frozen section; thin cutting, such as, for example, microtome cutting; mounting on a microscopic slide; and/or staining.
Types of staining applied on the histological section may depend on the tissue or organ and on the lesion to be detected.

In one embodiment of the invention, the biopsy sample is a liver biopsy sample, and the histological section of said liver biopsy sample is stained with picro-sirius red. This staining highlights the fibrosis in red, healthy tissues in yellow/orange and steatosis in white (i.e. optically empty).

In one embodiment of the invention, the histological section is then scanned in order to obtain the electronic or digital image that will be analyzed in the method of the invention. An example of scan parameters is by using an Aperio digital slide scanner (Scanscope CS System, Aperio Technologies, USA) image processor that provides high quality 30 000 x 30 000 pixel images at a resolution of 0.5 μm/pixel (magnification x20).

In another embodiment of the invention, the histological section is observed by an optical technique, preferably microscopic physical imaging, such as, for example electron microscopy, second harmonic generation (SHG), multiphoton imaging, coherent anti-Stokes Raman scattering - CARS), two-photon excitation fluorescence (TPEF), diffuse optical imaging or event-related optical signal, and the resulting image is then recovered to be analyzed in the method of the present invention.

In one embodiment of the invention, the at least one image is an image from an organ in a living organism provided by a non-invasive method. In one embodiment, the image is a three-dimensional image recovered on a living organism by a non-invasive method.

In one embodiment, the at least one image is a three dimensional image, preferably an image of an entire organ or organism, more preferably, said image is non-invasively recovered on a living organism. According to one embodiment, the three dimensional image is in the form of several slices distant from about 1 mm to about 10 cm, preferably from about 5 mm to about 1 cm, and more preferably of about 10 mm. In one embodiment, the image analysis of each of the images of these slices is performed as described for a histological section image.

Examples of methods that may be used for recovering an image of an organ in a living organism include, but are not limited to, non-optical techniques, such as, for example, non-optical techniques selected from the group comprising radiography (such as, for example, X-ray, ultrasonography, tomodensitometry (TDM), computerized scanner, magnetic resonance imaging (MRI), functional magnetic resonance imaging, tomography, computed axial tomography, proton emission tomography (PET) or single photon emission computed tomography); nuclear medicine (such as, for example, scintigraphy); photoacoustic methods; thermal methods; and magnetoencephalography.

In one embodiment of the invention, the at least one image is obtained by an optical technique, preferably microscopic physical imaging, such as, for example electron microscopy, second harmonic generation (SHG), multiphoton imaging, coherent anti-Stokes Raman scattering - CARS), two-photon excitation fluorescence (TPEF), diffuse optical imaging or event-related optical signal.

In another embodiment of the invention, the at least one image is obtained by a non-optical technique, preferably selected from the group comprising radiography, such as, for example, X-ray, ultrasonography, tomodensitometry (TDM), computerized scanner, magnetic resonance imaging (MRI), functional magnetic resonance imaging, tomography, computed axial tomography, proton emission tomography (PET) or single photon emission computed tomography; and nuclear medicine, such as, for example, scintigraphy; photoacoustic methods; thermal methods; and magnetoencephalography.

In one embodiment of the invention, the image is pre-treated before its analysis by the method of the invention.

Examples of pre-treatment include, but are not limited to, compression, transformation of the image in a binary image, such as, for example, a black and white image; removal of artefacts and the like.

In one embodiment of the invention, in order to facilitate sharing and storage of images, these may be compressed, such as, for example, using a JPEG2000 software.

The skilled artisan is a specialist of analysis of images of organs and tissues, and knows what artefacts should be removed before analysis of the image. Examples of artefacts that may be removed from the image include, but are not limited to folds, dust, and optionally large blood vessels, large biliary tracts and the like. In one embodiment, pre-treatment of the image comprises elimination of very small areas, considered as noise, elimination of vessels surrounding fibrosis, elimination of non-round regions, such as, for example, biliary tracts, or elimination of heterogeneous regions, such as, for example, blood vessels.

In one embodiment, pre-treatment of the image comprises detecting the white background of the image so that it is not taken into account in the analysis.

In one embodiment of the invention, the at least one, preferably the at least two descriptors are selected from the group comprising or consisting of fractal dimension of the edges of the organ or fragment thereof (DF_EDGE), linearity percentage of the edges (PCT_RECT), nodularity of the curved and irregular edges of the organ (ORGAN_NODULARITY), angularity (ORGAN_ANGULARITY), length of the organ or fragment thereof (ORGAN_LENGTH), length of a biopsy (BIOPSY_LENGTH), such as, for example, length of a liver biopsy (LB_LENGTH), length of numeric specimen (N_LENGTH), height of the organ (ORGAN_HEIGHT), perimeter of the organ or fragment thereof (ORGAN_PERIMETER), mean and total native perimeter of the organ (MEAN_NAT_ORGAN_PERIMETER and...
TOST_NAT_ORGAN_PERIMETER), smoothed perimeter of the organ (SMOOTH_ORGAN_PERIMETER), ratio between
the native and smoothed perimeters, also referred as anfractuosity (RATIO_ORGAN_PERIMETER), largest perimeter
of the organ (LARGEST_ORGAN_PERIMETER), indentation of the organ (ORGAN_INDENTATION), area of the organ
or fragment thereof (ORGAN_AREA), granularity percentage (PCT_GRANULARITY), fragmentation
(INDEX_FRAGMENTATION), mean intensity of the image on the red component (IlbR), mean intensity of the image on
the green component (IlbG), area of fibrosis (AOF), fractal dimension of fibrosis (DF), mean of percentage of fibrosis around areas (PCT_NOD), number of nodules (NB_NOD), number of nodules with more than 30% of fibrosis around (NB_NOD_30), area of steatosis (AOS), relative area of steatosis (rAOS), fractal dimension of steatosis (DS), area of porto-septal fibrosis (AO_FPORT), fractal dimension of porto-septal fibrosis (DF_FPORT), area of peri-sinusoidal fibrosis (AO_FPS), fractal dimension of peri-sinusoidal fibrosis (DF_FPS), area of lobular peri-sinusoidal fibrosis (AO_FPS_LOB), ratio of peri-sinusoidal fibrosis among the whole fibrosis (RATIO_FPS), luminosity of fibrosis staining in the red, green and/or blue components (IfibR, IfibG, and/or IfibB, respectively), luminosity of the parenchyma staining in the red, green and/or blue components (IparenchymaR, IparenchymaG, and/or IparenchymaB respectively), luminosity contrast between fibrosis and parenchyma (Contrast_Fib_Parenchyma), luminosity contrast between fibrosis and the organ or fragment thereof (Contrast_Fib_Lb), area of stellar fibrosis among the surface of the LB specimen (AOF_STELLAR_TOT), area of stellar fibrosis among the surface of porto-septal regions (AOF_STELLAR_EP), area of stellar fibrosis among the surface of lobular regions (AOF_STELLAR_LOB), number of porto-septal regions (NB_PORT), mean area of stellar fibrosis (MEAN_STELLAR_PORT), mean area of porto-septal regions (MEAN_AO_PORT), number of bridges (NB_BRIDGE), ratio of bridges among the porto-septal areas (RATIO_BRIDGE), area of fibrosis in the bridges (AOF_BRIDGE), bridges thickness (MEAN_THICK_BRIDGE), bridges perimeter (MEAN_PERIM_BRIDGE), bridges surface (MEAN_SURF_BRIDGE), portal distance (DIST_EP_MEAN), organ fat ratio (ORGAN_FAT), abdominal fat ratio (ABDO_FAT), hypertrophy of liver segment I (LIVER_HYPERTROPHY), surface of the segment I (Surf_S1), width of the liver segment IV (WIDTH_S4), ratio between segment I and segment IV dimensions (RATIO_S1_S4), furrow thickness (D_F1), surface of the furrow I (Surf_F1), internal nodularity in the liver (LIVER_NODULARITY), diameter of the portal vein (PORT_DIAMETER), heterogeneity of the density intensity (HETEROGENEITY), fractal organization of the organ (ORGAN_FRACT).

[0059] Another object of the invention is thus a selector described from the group comprising fractal dimension of the edges of the organ or fragment thereof (DF_EDGE), linearity percentage of the edges (PCT_RECT), nodularity of the curved and irregular edges of the organ (ORGAN_NODULARITY), angularity (ORGAN_ANGULARITY), length of the organ or fragment thereof (ORGAN_LENGTH), length of a biopsy (BIOPSY_LENGTH), such as, for example, length of a liver biopsy (LB_LENGTH), length of numeric specimen (N_LENGTH), height of the organ (ORGAN_HEIGHT), perimeter of the organ or fragment thereof (ORGAN_PERIMETER), mean and total native perimeter of the organ (MEAN_NAT_ORGAN_PERIMETER and TOT_NAT_ORGAN_PERIMETER), smoothed perimeter of the organ (SMOOTH_ORGAN_PERIMETER), ratio between the native and smoothed perimeters (RATIO_ORGAN_PERIMETER), largest perimeter of the organ (LARGEST_ORGAN_PERIMETER), indentation of the organ (ORGAN_INDENTATION), area of the organ or fragment thereof (ORGAN_AREA), granularity percentage (PCT_GRANULARITY), fragmentation (INDEX_FRAGMENTATION), mean intensity of the image on the red component (IlbR), mean intensity of the image on the green component (IlbG), area of fibrosis (AOF), fractal dimension of fibrosis (DF), mean of percentage of fibrosis around areas (PCT_NOD), number of nodules (NB_NOD), number of nodules with more than 30% of fibrosis around (NB_NOD_30), area of steatosis (AOS), relative area of steatosis (rAOS), fractal dimension of steatosis (DS), area of porto-septal fibrosis (AO_FPORT), fractal dimension of porto-septal fibrosis (DF_FPORT), area of peri-sinusoidal fibrosis (AO_FPS), fractal dimension of peri-sinusoidal fibrosis (DF_FPS), area of lobular peri-sinusoidal fibrosis (AO_FPS_LOB), ratio of peri-sinusoidal fibrosis among the whole fibrosis (RATIO_FPS), luminosity of fibrosis staining in the red, green and/or blue components (IfibR, IfibG, and/or IfibB, respectively), luminosity of the parenchyma staining in the red, green and/or blue components (IparenchymaR, IparenchymaG, and/or IparenchymaB respectively), luminosity contrast between fibrosis and parenchyma (Contrast_Fib_Parenchyma), luminosity contrast between fibrosis and the organ or fragment thereof (Contrast_Fib_Lb), area of stellar fibrosis among the total surface of the LB specimen (AOF_STELLAR_TOT), area of stellar fibrosis among the surface of porto-septal regions (AOF_STELLAR_EP), area of stellar fibrosis among the surface of lobular regions (AOF_STELLAR_LOB), number of porto-septal regions (NB_PORT), mean area of stellar fibrosis (MEAN_STELLAR_PORT), mean area of porto-septal regions (MEAN_AO_PORT), number of bridges (NB_BRIDGE), ratio of bridges among the porto-septal areas (RATIO_BRIDGE), area of fibrosis in the bridges (AOF_BRIDGE), bridges thickness (MEAN_THICK_BRIDGE), bridges perimeter (MEAN_PERIM_BRIDGE), bridges surface (MEAN_SURF_BRIDGE), portal distance (DIST_EP_MEAN), organ fat ratio (ORGAN_FAT), abdominal fat ratio (ABDO_FAT), hypertrophy of liver segment I (LIVER_HYPERTROPHY), surface of the segment I (Surf_S1), width of the liver segment IV (WIDTH_S4), ratio between segment I and segment IV dimensions (RATIO_S1_S4), furrow thickness (D_F1), surface of the furrow I (Surf_F1), internal nodularity in the liver (LIVER_NODULARITY), diameter of the portal vein (PORT_DIAMETER), heterogeneity of the density intensity (HETEROGENEITY), fractal organization of the organ (ORGAN_FRACT).
vein (PORT_DIAMETER), heterogeneity of the density intensity (HETEROGENEITY) and fractal organization of the organ (ORGAN_FRACT).

[0060] Description of these descriptors and examples of methods for measuring thereof are given hereinafter.

- Measure of edge linearity:

[0061] The analysis of the edges of an organ or of a fragment thereof is an important descriptive factor for assessing the presence and/or the severity of a lesion or for diagnosing a disease.

[0062] In one embodiment, in order to measure edge linearity, the edges of the organs or fragments thereof are detected leading to a mask (MASK_EDGE). Then, the Hough transform is applied to detect straight lines on MASK_EDGE (Duda et al, Comm ACM, 1972, 15:11-15), leading to a mask called MASK_HOUGH containing only the edges of the mask detected as straight by the Hough transform. In parallel, a straight mask MASK_RECT is created from the edge mask (MASK_EDGE), using a Harris detector (Harris et al, Proceedings of the 4th Alvey Vision Conference, 1988:147-151). Therefore, MASK_RECT represents the edges of MASK_EDGE that are in common with this theoretical straight mask. Then, a third mask is obtained by the combination of both previous masks: MASK_RECTCOMB (MASK_RECTCOMB = MASK_HOUGH + MASK_RECT). MASK_RECTCOMB thus contains all the straightest edges of the organ or fragment thereof. The descriptors associated with edge linearity are the following:

- Fractal dimension of the edges (DF_EDGE): refers to the fractal dimension of the edges of the organ or fragment thereof on MASK_EDGE. Methods for determining fractal dimensions are well known from the skilled artisan. Examples of such methods include, but are not limited to the "box-counting" method (Moal et al, Hepatology, 2002, 36:840-849).
- Linearity percentage of the edges (PCT_RECT): is determined according to the following formula:

\[ PCT\_RECT = \frac{\text{Pix}_{\text{MaskRectComb}}}{\text{Pix}_{\text{MaskEdge}}} \times 100 \]

wherein \( \text{Pix}_{\text{MaskRectComb}} \) is the number of pixels of \( \text{MASK}\_\text{RECTCOMB} \) and \( \text{Pix}_{\text{MaskEdge}} \) is the number of pixels of \( \text{MASK}\_\text{EDGE} \).

- Measure of the length of an organ or fragment thereof (ORGAN_LENGTH):

For measuring the length of the organ or fragment thereof on the image, a mask obtained after the elimination of the artefacts (MASK_ORGAN) may be used: a morphometric operation (skeletonization) is applied and gives a skeleton of the organ or fragment thereof. Then, small ramifications may be removed in order to keep the main skeleton (MASK_SKELETON) that represents the organ’s length.

\[ \text{ORGAN\_LENGTH} = \frac{\text{Pix}_{\text{ORGAN\_SKELETON}} \times \text{IM\_Resolution} \times R\_SCALE}{\text{Pix}_{\text{MaskEdge}}} \]

wherein \( \text{Pix}_{\text{ORGAN\_SKELETON}} \) is the number of pixels that represent the organ length on \( \text{MASK}\_\text{ORGAN} \), \( \text{IM\_Resolution} \) is the resolution of the scanned image and \( R\_SCALE \) is the scale factor used to resize the image. In one embodiment of the invention, \( \text{IM\_Resolution} \) is of about 0.5 \( \mu \text{m} \). In another embodiment of the invention, \( R\_SCALE \) is of about 4.

[0063] In one embodiment, the same operations may be carried out for measuring the length of a biopsy sample (BIOPSY_LENGTH), such as, for example, the length of a liver biopsy (LB_LENGTH). In one embodiment, the same operations may be carried out for measuring the length of a numeric specimen (N_LENGTH).

- Measure of the perimeter:

[0064] The measure of the perimeter of the organ or fragment thereof (ORGAN_PERIMETER) comprises detecting, preferably automatically detecting, the edges of the fragments on the organ specimen and, thanks to the mask \( \text{MASK}\_\text{EDGE} \) (see hereinafore), calculating the perimeter as follows:

\[ \text{ORGAN\_PERIMETER} = \frac{\text{Pix}_{\text{MaskEdge}} \times \text{IM\_Resolution} \times R\_SCALE}{\text{Pix}_{\text{MaskEdge}}} \]

wherein \( \text{Pix}_{\text{MaskEdge}} \) is the number of pixels of \( \text{MASK}\_\text{EDGE} \), \( \text{IM\_Resolution} \) is the resolution of the scanned image (preferably
about 0.5 μm) and $R_{\text{SCALE}} = 4$ is the scale factor used to resize the image.

- **Measure of the area:**

[0065] The measure of the area of the organ or fragment thereof (ORGAN_AREA) comprises detecting, preferably automatically detecting, the edges of the fragments on the organ specimen and, thanks to the mask $\text{MASK}_{\text{EDGE}}$ (see hereinabove), calculating the area as follows:

$$\text{ORGAN\_AREA} = \text{Pix}_{\text{MASK\_ORGAN}} \times IM_{\text{Resolution}}^2 \times R_{\text{SCALE}}^2,$$

wherein $\text{Pix}_{\text{MASK\_ORGAN}}$ is the number of pixels of the total area of the organ specimen or fragment thereof, $IM_{\text{Resolution}}$ is the resolution of the scanned image (preferably about 0.5 μm) and $R_{\text{SCALE}} = 4$ is the scale factor used to resize the image.

- **Measure of granularity:**

[0066] The measure of the granularity percentage (PCT_GRANULARITY) aims at quantifying the impairment of the structure (i.e., destructuration) of an organ or tissue due to the presence of a lesion. $\text{PCT}_{\text{GRANULARITY}}$ is the ratio between the number of fragments without destructuration and the number of granules obtained in these fragments after destructuration by porto-septal areas:

$$\text{PCT}\_\text{GRANULARITY} = 100 - (\text{NB}\_\text{FRAG} / \text{Nb}\_\text{Granules} \times 100)$$

wherein $\text{NB}\_\text{FRAG}$ is the number of fragment in the analysed area and $\text{Nb}\_\text{Granules}$ is the number of granules obtained in these fragments.

- **Measure of fragmentation:**

[0067] An organ or tissue specimen is sometimes fragmented, depending on the presence of lesions. A mask obtained after the elimination of the artefacts ($\text{MASK}\_\text{ORGAN}$) may be used for measuring said fragmentation: detection on this mask of small fragments leads to another mask: $\text{MASK}\_\text{FRAG\_SMALL}$.

[0068] In one embodiment, a fragment is considered as small if its surface is lower than or equal to about 5 mm², preferably lower than or equal to about 3 mm², more preferably lower than or equal to about 2 mm².

[0069] In another embodiment, a fragment is considered as small if its surface is lower than or equal to about 7 mm², preferably lower than or equal to about 5 mm², more preferably lower than or equal to about 3 mm², if this fragment has a circularity up to 0.7. The fragmentation index is the ratio between the surface of small fragments detected and the total surface of the organ specimen:

$$\text{INDEX}\_\text{FRAGMENTATION} = \text{Pix}\_\text{Mask}\_\text{Frag\_Small} / \text{Pix}\_\text{Mask}\_\text{Frag} \times 100$$

wherein $\text{Pix}\_\text{Mask}\_\text{Frag}$ is the number of pixels in $\text{MASK}\_\text{ORGAN}$ and $\text{Pix}\_\text{Mask}\_\text{Frag\_Small}$ the number of pixel in $\text{MASK}\_\text{FRAG\_SMALL}$.

- **Quality of the image:**

[0070] All the measures of intensity luminosity are applied on the three components of the image (RGB: Red, Green and Blue). The luminosity intensity of the image is calculated by averaging all pixel intensities. Descriptors corresponding to the mean intensity for each component are measured: ILbR (mean intensity of the image on the red component), ILbG (mean intensity of the image on the green component) and ILbB (mean intensity of the image on the blue component).

[0071] In one embodiment of the invention where the lesion is fibrosis, the following descriptors may be assessed:

- **- Area of Fibrosis (AOF):**

AOF is equal to the ratio of pixels of fibrosis divided by the number of pixels in the studied area:
wherein $Pix_{FIB}$ is the number of fibrosis pixels and $Pix_{MASK\_PBH}$ is the number of pixels of the studied area.

- Fractal dimension of fibrosis ($D_F$):

In one embodiment of the invention, when the descriptor is a data regarding fractal properties of the organ or tissue, fractal dimension may be measured using the "box-counting" method (Moal et al, Hepatology, 2002, 36:840-849). The box-counting method provides the fractal dimension of Kolmogorov ($D$). The technique has been reported in details for biological structures. Briefly, a grid of square boxes (with $\epsilon$ pixels as the side length) resembling a chessboard is superimposed over the histologic image of threshold fibrosis. Boxes intersecting with collagen fibers are counted. Another chessboard grid is then used to cover the entire surface of the microscopic field. Thus, the total number ($N$) of boxes of sides ($\epsilon$) required to completely cover the collagen fibers reflects the perimeter examined with the scale ratio $\epsilon$. In one embodiment, this step is repeated with $\epsilon$ varying until a size of about 14 pixels, and data are plotted on a log-log graph (i.e., log $N$ against log[\(\epsilon\)]). The relationship between points is measured by linear regression analysis using the least square method; the slope $D_F$ of the regression line corresponds to the fractal dimension of fibrosis $D_F$.

- Measure of nodules:

Nodules are the result of the disruption of fibrosis that circles regions of tissue (parenchyma), that may be defined as circular and non-fibrotic (without fibrous septa inside) area surrounded by fibrosis. Two descriptors associated with the presence of nodules are measured: mean of percentage of fibrosis around areas ($PCT\_NOD$) and number of nodules ($NB\_NOD$). Measure of $PCT\_NOD$ is carried out the same way as $PCT\_GRANULARY$, wherein only the circular granules are kept. In one embodiment, as nodules are not always perfectly round, granules having a circularity of at least about 0.3, preferably at least about 0.4, more preferably at least about 0.45 are considered as nodules. In one embodiment, among the round or quite-round granules, those having at least about 10%, preferably at least about 20%, more preferably at least about 30% of fibrosis around (i.e. at least about 10, 20 or 30% of the external border) are considered as nodules. Finally, a mask with regions tending towards nodularity ($MASK\_NOD$) is obtained. In one embodiment, nodules were considered as definitive when $PCT\_GRANULARY$ was of at least 50%, preferably at least 70%, more preferably of at least 80%. The descriptors associated with the measure of nodules are the following:

\[
PCT\_NOD = \text{mean of percentage of fibrosis around areas in } MASK\_NOD.
\]

\[
NB\_NOD = \text{number of nodules in } MASK\_NOD \text{ with more than 80\% of fibrosis around.}
\]

In one embodiment, the number of nodules in $MASK\_NOD$ with more than 30% of fibrosis around ($NB\_NOD\_30$) is calculated, according to the following formula:

\[
NB\_NOD = \text{number of nodules in } MASK\_NOD \text{ with more than 30\% of fibrosis around.}
\]

In one embodiment of the invention where the lesion is steatosis, the following descriptors may be assessed:

- Area of Steatosis ($AOS$):

$AOS$ is equal to the ratio of pixels of steatosis divided by the number of pixels in the studied area:

\[
AOS = \frac{Pix\_STEA}{Pix_{MASK\_PBH}} \times 100
\]

wherein $Pix\_STEA$ is the number of steatosis pixels and $Pix_{MASK\_PBH}$ is the number of pixels of the studied area.
- Relative Area of Steatosis (rAOS):

[0077] This descriptor corresponds to the area of steatosis in the non-fibrotic area of the image.

- Fractal dimension of steatosis (DS):

[0078] Fractal dimension of steatosis may be measured according to the method already described for measuring the fractal dimension of fibrosis (see hereinabove) using images showing steatosis.

[0079] In one embodiment of the invention where the organ is liver and the lesion is fibrosis, the following descriptors may be assessed:

- Area and fractal dimension of porto-septal and peri-sinusoidal fibrosis:

[0080] Fibrosis can start in the centro-lobular region (alcoholic liver disease) and/or in the periphery of the liver lobule or around the portal tracts (viral liver disease). This fibrosis grows gradually to form bands of fibrosis, or septa, called septal fibrosis. This septal fibrosis is extended between the portal tracts or between the portal tracts and the centro-lobular region. The cirrhosis stage occurs when these different septa entirely surround hepatocytes. When pathologists are assessing the Metavir stage, their judgment is based on the porto-septal fibrosis. The other form of fibrosis is located between the rows of hepatocytes and sinusoids, the equivalent of the capillary in the liver, that is to say, in the intercellular space where there are many liver metabolic exchanges. This is called the peri-sinusoidal fibrosis. Although it is not taken into account in the fibrosis scores in clinical use, this fibrosis is important because it has a key role in the genesis of liver failure and portal hypertension. The Inventors thus developed a mask ($\text{MASKPORT}$) which allows distinguishing porto-septal and peri-sinusoidal fibrosis. In one embodiment, as the creation of this mask requires a large number of morphometric treatments (regarding erosions, dilations, the size of fibrosis areas...) the image dimensions may be reduced.

[0081] In one embodiment of the invention, the image is pretreated by at least one of the following steps: (i) as peri-sinusoidal fibrosis lies between the rows of hepatocytes; therefore, it is sufficient to eliminate it by detecting the hepatocytes which have the intensity of healthy tissue; (ii) concerning veins and vessels, if their diameter is less than about 500 μm, preferably less than about 350 μm, more preferably less than about 200 μm and if the fibrosis around is small compared to their size, they are not considered in the $\text{MASKPORT}$.

[0082] In one embodiment, as porto-septal regions have a lot of fibrosis, the elements of fibrosis with large areas are considered in the $\text{MASKPORT}$. In another embodiment, the fractal dimension of fibrosis into these regions is a further criterion to determine if these regions are in $\text{MASKPORT}$. In one embodiment, thin regions (small ratio between the perimeter of the area and its surface) with nodes (interconnection points in fibrosis filaments), which is a sign of branched forms as observed in peri-sinusoidal fibrosis, are not considered as porto-septal fibrosis.

[0083] The descriptors assessing porto-septal and/or peri-sinusoidal fibrosis are the following:

- **Area of porto-septal fibrosis ($\text{AO_FPORT}$):**

$$\text{AO_FPORT} = \frac{\text{Pix_FPORT}}{\text{PixMASK_LB}} \times 100$$

wherein $\text{Pix_FPORT}$ is the number of pixels of porto-septal fibrosis and $\text{PixMASK_LB}$ is the number of pixels of the total area of the LB specimen.

- **Fractal dimension of porto-septal fibrosis ($\text{DF_FPORT}$):** fractal dimension of porto-septal fibrosis may be measured according to the method already described for measuring the fractal dimension of fibrosis (see hereinabove).

- **Area of peri-sinusoidal fibrosis ($\text{AOFPS}$)**

$$\text{AOFPS} = \frac{\text{PixFPS}}{\text{PixMASK_LB}} \times 100$$

wherein $\text{PixFPS}$ is the number of pixels of peri-sinusoidal fibrosis and $\text{PixMASK_LB}$ is the number of pixels of the total area of the LB specimen.

- **Fractal dimension of peri-sinusoidal fibrosis ($\text{DF FPS}$):** fractal dimension of peri-sinusoidal fibrosis may be measured according to the method already described for measuring the fractal dimension of fibrosis (see hereinabove).

- **Area of lobular peri-sinusoidal fibrosis ($\text{AO_FPS_LOB}$)**
wherein \( \text{PixFPS} \) is the number of pixels of peri-sinusoidal fibrosis, \( \text{PixMASK}_{\text{LB}} \) is the number of pixels of the total area of the LB specimen and \( \text{Pix}_\text{Mask}_\text{Port} \) is the number of pixels of the porto-septal area.

\[
\text{RATIO FPS} = \frac{\text{PixFPS}}{\text{PixFIB}_{\text{TOT}}} \times 100
\]

wherein \( \text{PixFPS} \) is the number of pixels of peri-sinusoidal fibrosis and \( \text{PixFIB}_{\text{TOT}} \) is the number of pixels representing all the fibrosis (porto-septal and peri-sinusoidal fibrosis).

- Quality of the staining:

[0084] In one embodiment wherein the lesion is fibrosis, the measure of the quality of the image as hereinabove described may further comprise measurement of the luminosity of fibrosis staining in the red, green and blue components (\( \text{IfibR}, \text{IfibG}, \text{and IfibB} \)) and of the luminosity parenchyma staining in the red, green and blue components (\( \text{IparenchymaR}, \text{IparenchymaG}, \text{and IparenchymaB} \)). As the quality of the coloration may also be considered as insufficient if the fibrosis intensity is closed to the intensity of the parenchyma or the LB (i.e. if there is only a weak contrast between the fibrosis and the parenchyma or LB), descriptors assessing said contrast were developed: luminosity contrast between fibrosis and parenchyma (\( \text{Contrast}_{\text{Fib-Parenchyma}} \)) and luminosity contrast between fibrosis and the organ or fragment thereof (\( \text{Contrast}_{\text{Fib-LB}} \)). These are measured as follows:

\[
\text{Contrast}_{\text{Fib-Parenchyma}} = \sqrt{(\text{IparenchymaR} - \text{IfibR})^2 + (\text{IparenchymaG} - \text{IfibG})^2 + (\text{IparenchymaB} - \text{IfibB})^2}
\]

\[
\text{Contrast}_{\text{Fib-LB}} = \sqrt{(\text{ILbR} - \text{IfibR})^2 + (\text{ILbG} - \text{IfibG})^2 + (\text{ILbB} - \text{IfibB})^2}
\]

- Measure of stellar fibrosis:

[0085] Stellar fibrosis may be defined as fibrosis patterns with small and fine fibrils around a more dense area. Stellar fibrosis usually appears around the portal tracts. Therefore, stellar fibrosis is assessed in the method of the present invention using the following descriptors: area of stellar fibrosis among the total surface of the LB specimen (\( \text{AOF}_{\text{STELLAR}_{\text{TOT}}} \)), area of stellar fibrosis among the surface of porto-septal regions (\( \text{AOF}_{\text{STELLAR}_{\text{EP}}} \)) and area of stellar fibrosis among the surface of lobular regions (\( \text{AOF}_{\text{STELLAR}_{\text{LOB}}} \)); number of porto-septal regions (\( \text{NB}_{\text{PORT}} \)); mean area of stellar fibrosis (\( \text{MEAN}_{\text{STELLAR}_{\text{PORT}}} \)) and mean area of porto-septal regions (\( \text{MEAN}_{\text{AO}_{\text{PORT}}} \)). In one embodiment, fibrosis is detected in a distance of about 1000 µm, preferably of about 500 µm, more preferably of about 100 µm around the porto-septal regions on a mask allowing the separation of peri-sinusoidal fibrosis from porto-septal fibrosis (\( \text{MASK}_{\text{PORT}} \)). Descriptors assessing stellar fibrosis are the following:

\[
\text{AOF}_{\text{STELLAR}_{\text{TOT}}} = \frac{\text{Pix}_{\text{Fib-Stellar}}}{\text{PixMASK}_{\text{LB}}} \times 100
\]

\[
\text{AOF}_{\text{STELLAR}_{\text{EP}}} = \frac{\text{Pix}_{\text{Fib-Stellar}}}{\text{PixMask}_\text{Port}} \times 100
\]

\[
\text{AOF}_{\text{STELLAR}_{\text{LOB}}} = \frac{\text{Pix}_{\text{Fib-Stellar}}}{(\text{PixMASK}_{\text{LB}} - \text{PixMask}_\text{Port})} \times 100
\]

\[
\text{MEAN}_{\text{STELLAR}_{\text{PORT}}} = \frac{\text{Pix}_{\text{Fib-Stellar}}}{\text{NB}_{\text{PORT}}}
\]
WHEREIN \textit{Pix\_Fib\_Stellar} is the number of pixels detected as stellar fibrosis, \textit{Pix\_MASK\_LB} is the number of pixels of the total area on the liver biopsy specimen, \textit{Pix\_Mask\_Port} is the number of pixels of the porto-septal area in \textit{MASK\_PORT} and \textit{NB\_PORT} is the number of porto-septal regions in \textit{MASK\_PORT}.

- Measure of bridging fibrosis:

As used herein, a bridge refers to a situation where two portal tracts are interconnected. A bridge may thus be defined as a structure lying between two thick elements. For assessing bridging fibrosis, the following descriptors may be measured in the method of the invention: number of bridges (\textit{NB\_BRIDGE}), ratio of bridges among the porto-septal areas (\textit{RATIO\_BRIDGE}), area of fibrosis in the bridges (\textit{AOF\_BRIDGE}), bridges thickness (\textit{MEAN\_THICK\_BRIDGE}), bridges perimeter (\textit{MEAN\_PERIM\_BRIDGE}) and bridges surface (\textit{MEAN\_SURF\_BRIDGE}).

In one embodiment, for each porto-septal region in \textit{MASK\_PORT} (the construction of \textit{MASK\_PORT} is described hereinabove), morphometric operations such as, for example, high erosion followed by a small dilation are applied. The aim is to observe a separation of the structures which determines the presence of bridges. At the end of the morphometric operations, a studied area with at least two elements is considered as a bridge and added in the \textit{MASK\_BRIDGE}.

Descriptors are measured as follows:

\begin{itemize}
    \item \textit{NB\_BRIDGE} is the number of bridges in \textit{MASK\_BRIDGE}
    \item \textit{RATIO\_BRIDGE} = \frac{\textit{Pix\_Mask\_Bridge}}{\textit{Pix\_Mask\_Port}} \times 100
    \item \textit{AOF\_BRIDGE} = \frac{\textit{Pix\_Fib\_Bridge}}{\textit{Pix\_MASK\_LB}} \times 100
\end{itemize}

wherein \textit{Pix\_Mask\_Port} is the number of pixels in \textit{MASK\_PORT}, \textit{Pix\_Mask\_Bridge} is the number of pixels in \textit{MASK\_BRIDGE}, \textit{Pix\_Fib\_Bridge} is the number pixels of fibrosis in the bridges, and \textit{Pix\_MASK\_LB} is the number of pixels of the total area on the LB specimen.

\begin{equation}
\text{MEAN\_THICK\_BRIDGE} = \frac{\text{MEAN\_SURF\_BRIDGE}}{\text{MEAN\_PERIM\_BRIDGE}} \times 100
\end{equation}

wherein \textit{MEAN\_SURF\_BRIDGE} is the mean of pixels representing the surface of bridges and \textit{MEAN\_PERIM\_BRIDGE} is the mean of pixels representing the perimeter of bridges.

- Measure of portal distance (\textit{DIST\_EP\_MEAN})

As the distance between portal tracts tends to reduce when fibrosis progresses, descriptors assessing the portal distance were developed: \textit{NB\_FRAG} is the number of fragments in \textit{MASK\_LB} and \textit{NB\_EP\_n} is the number of porto-septal regions present on the fragment \textit{n} (wherein \textit{n} ranges between 1 and \textit{NB\_FRAG}). For each \textit{n} fragment, the minimum distance \textit{Dmin\_n} between all porto-septal regions present on \textit{MASK\_PORT} are measured. \textit{Dmoy\_n} is the average distance between regions on the porto-septal fragment \textit{n}.

\[ Dmoy\_n = Dmin\_n / (Nb\_EP\_n - 1). \]

The average distance between porto-septal regions for all fragments is called \textit{DIST\_EP\_MEAN}:

\begin{equation}
\text{DIST\_EP\_MEAN} = \frac{(Dmoy\_1 + Dmoy\_2 + \ldots + Dmoy\_{NB\_FRAG})}{NB\_FRAG}.
\end{equation}
In one embodiment wherein the image is a three-dimensional image, such as, for example, an image of an entire organ, the following descriptors may be assessed:

- **External morphology descriptors:**
  - the characteristic of anfractuosity is assessed with the following descriptors:
    - mean (MEAN_NAT_ORGAN_PERIMETER) and total native perimeter of the organ (TOT_NAT_ORGAN_PERIMETER),
    - smoothed perimeter of the organ (SMOOTH_ORGAN_PERIMETER),
    - ratio between the native and smoothed perimeters (RATIO_ORGAN_PERIMETER).
  - largest perimeter of the organ (LARGEST_ORGAN_PERIMETER),
  - indentation of the organ (ORGAN_INDENTATION),
  - height (ORGAN_HEIGHT),
  - fractal dimension of the edges of the organ (DF_EDGE),
  - nodularity of the curved and irregular edges of the organ (ORGAN_NODULARITY),
  - angularity (representing the angles present on the edges) (ORGAN_ANGULARITY).
- In one embodiment, a box containing the organ is drafted and the following descriptors are assessed:
  - organ fat ratio (black pixels vs other pixels; ORGAN_FAT)
  - abdominal fat ratio (black pixels vs other pixels contained in the abdomen; ABDO_FAT).

- **Internal morphology descriptors:** In one embodiment wherein the organ is the liver, the following descriptors may be assessed:
  - hypertrophy of liver segment I (LIVER_HYPERTROPHY) which is observed in the high Metavir fibrosis stages. Methods for measuring hypertrophy are known from the skilled artisan, and a particular method for measuring hypertrophy is shown in the Examples. Briefly, said method includes, using the inferior cave vein as a landmark, measuring 2 antero-posterior lengths (D1 and D3), 2 transversal lengths (D2 and D4) and the surface of the segment I (Surf_S1),
  - width of the liver segment IV (WIDTH_S4), and
  - ratio between segment I and segment IV dimensions (RATIO_S1_S4)
  - furrow thickness (D_F1),
  - surface of the furrow I (Surf_F1),
  - internal nodularity in the liver (LIVER_NODULARITY),
  - diameter of the portal vein (PORT_DIAMETER).

- **Structure of the organ:** the following descriptors may be assessed:
  - heterogeneity of the density intensity (HETEROGENEITY),
  - fractal organization of the organ (ORGAN_FRACT).

Methods for measuring these three-dimensional image descriptors are shown in the Examples. The method of the invention may be applied to any organ or tissue of an organism. In one embodiment of the invention, the organ or tissue is susceptible to comprise fibrosis. Examples of organs or tissues susceptible to comprise fibrosis include, but are not limited to, liver, skin, heart, lung, kidney, gut, intestine, pancreas, bone marrow, joints, and soft tissues, such as, for example, soft tissue of the mediastinum or soft tissue of the retroperitoneum. In one embodiment of the invention, the organ or tissue is susceptible to comprise steatosis. Examples of organs or tissues susceptible to comprise steatosis include, but are not limited to, liver, kidney, heart and muscle (muscle may comprise steatosis in metabolic syndrome). In one embodiment of the invention, the organ or tissue is liver, and the lesion is preferably related to a liver disease. Examples of liver lesions include, but are not limited to, liver fibrosis, cirrhosis, liver steatosis or non-alcoholic steato-hepatitis (NASH). Examples of liver diseases include, but are not limited to, acute liver diseases and chronic liver diseases. Specific examples of liver diseases that may cause lesions to the liver include, but are not limited to chronic viral hepatitis C, chronic viral hepatitis B, chronic viral hepatitis D, chronic viral hepatitis E, non-alcoholic fatty liver disease (NAFLD),...
alcoholic chronic liver disease, autoimmune hepatitis, hemochromatosis, Wilson disease and acquired or inherited metabo-
lic disorder.

In one embodiment of the invention, the subject is an animal, preferably a mammal, such as for example, a rat or a pet, such as, for example, a cat or a dog. According to a preferred embodiment, the subject is a human. In one embodiment of the invention, the human is a male, a female or a child.

According to an embodiment, the subject, including a human, is at risk of presenting a lesion in an organ or a tissue; or presents a lesion in an organ or a tissue. In one embodiment, said risk may correspond to a familial predisposition to lesions, to a genetic predisposition to lesions, or to an environmental exposure to compounds or conditions promoting the appearance or development of lesions.

Examples of lesions whose presence and/or severity may be assessed by the method of the invention include, but are not limited to, fibrosis, steatosis, lesions induced by inflammation, tumors, polyps, nodules, cyst, ulcers, and the like.

In one embodiment of the invention, the lesion is fibrosis.

Fibrosis lesions can be distinguished according to their origin into different patterns. Therefore, in a first embodiment, the lesion includes fibrosis, such as, for example, fibrils or septa. In a second embodiment, the lesion does not comprise fibrosis but is secondary or related to fibrosis, such as, for example, parenchymal nodules, specimen fragmentation, irregular edges...

Moreover, fibrosis patterns can also be distinguished according to their development.

Therefore, in a first embodiment, the lesion is an elementary or primary lesion. Elementary or primary lesions are the smallest single lesions with pattern corresponding to an organized structure visible at the smallest usual magnification. For example, fibrosis fibers or fibrils are the basic pattern and stellar fibrosis is an elementary lesion.

They correspond to architectural distortions of first rank.

In a second embodiment, the lesion is a syndromic or secondary lesion. Syndromic or secondary lesions correspond to the grouping of elementary lesions. For example, bridging fibrosis is a secondary lesion by grouping stellar fibrosis arising from two portal tracts. They correspond to architectural distortions of second rank.

In one embodiment, the lesion is fibrosis and the organ or tissue is liver or liver tissue.

According to this embodiment, different types of fibrosis may be distinguished.

In a first embodiment of the invention, fibrosis may be distinguished according to its severity. Two main semi-quantitative diagnostic scores are commonly used by hepatologists and pathologists: the METAVIR fibrosis score and the ISHAK staging system. The METAVIR fibrosis score comprises 5 classes (F0: no fibrosis; F1: portal fibrosis without septa; F2: portal fibrosis with rare septa; F3: numerous septa without cirrhosis; F4: cirrhosis). The ISHAK staging system comprises 7 classes based on portal and septal fibrosis and the degree of completeness for cirrhosis.

In one embodiment, the lesion is clinically significant fibrosis, which is defined by a METAVIR fibrosis score F\geq2.

In another embodiment, the lesion is cirrhosis, which is defined by a METAVIR fibrosis score F=4.

In a second embodiment of the invention, fibrosis may be distinguished according to its localization and/or geometrical organization within the liver.

In one embodiment of the invention, fibrosis is portal fibrosis, septal fibrosis, porto-septal fibrosis or perisinusoidal fibrosis. Indeed, a first type of fibrosis usually starts in the centrolobular region and/or in the periphery of the lobule or around the portal tracts. This fibrosis grows gradually to form bands of fibrosis, or septa, called septal fibrosis, that will extends between the portal tracts or between the portal tracts and the centrolobular region. The second type of fibrosis is located between the rows of hepatocytes and sinusoids, the equivalent of the capillary in the liver, that is to say, in the intercellular space where there are many liver metabolic exchanges. This second type is called the perisinusoidal fibrosis.

In one embodiment of the invention, fibrosis is stellar fibrosis. The main feature to differentiate stage of fibrosis F0 from stage F1 and higher stages is the presence of star-branched fibrosis around porto-septal regions. These are small and fine fibrils around a more dense area.

In one embodiment of the invention, fibrosis is bridging fibrosis. Bridging fibrosis refers to a fibrosis situation wherein two portal tracts are interconnected. Bridging fibrosis fibers occur at the METAVIR stage F2, and pathologists consider that if there is a ratio of more than 50% of bridges, the METAVIR stage will be higher than F2.

In another embodiment of the invention, the lesion is steatosis.

In one embodiment of the invention, steatosis is liver steatosis, and is related to FLD (Fatty Liver Disease). FLD describes a wide range of potentially reversible conditions involving the liver, wherein large vacuoles of triglyceride fat accumulate in hepatocytes via the process of steatosis (i.e. the abnormal retention of lipids within a cell). FLD is commonly associated with alcohol or metabolic disorders (such as, for example, diabetes, hypertension, dyslipidemia, abetalipoproteinemia, glycogen storage diseases, Weber-Christian disease, Wolman disease, acute fatty liver of pregnancy or lipodystrophy). However, it can also be due to nutritional causes (such as, for example, malnutrition, total parenteral nutrition, severe weight loss, refeeding syndrome, jejuno-ileal bypass, gastric bypass or jejunal diverticulosis with bacterial overgrowth), as well as various drugs and toxins (such as, for example, amiodarone, methotrexate,
diltiazem, highly active antiretroviral therapy, glucocorticoids, tamoxifen or environmental hepatotoxins) and other diseases such as inflammatory bowel disease or HIV.

[0118] Whether it is AFLD (Alcoholic Fatty Liver Disease) or NAFLD (Non-Alcoholic Fatty Liver Disease), FLD encompasses a more serious spectrum consisting of the mildest type "liver steatosis" (fatty liver), called NAFL, to the potentially more serious type "steatohepatitis", called NASH, which is associated with liver-damaging inflammation and, sometimes, the formation of fibrous tissue. In fact, steatohepatitis has the inherent propensity to progress towards the development of fibrosis then cirrhosis which can produce progressive, irreversible liver scarring or towards hepatocellular carcinoma (liver cancer).

[0119] Therefore, in one embodiment, steatosis is simple liver steatosis or NAFL (Non-alcoholic fatty liver). In another embodiment, steatosis is part of steatohepatitis or NASH.

[0120] In one embodiment, the cause of steatosis is an alcohol or metabolic syndrome, such as, for example, Diabetes, hypertension, dyslipidemia, abetalipoproteinemia, glycogen storage diseases, Weber-Christian disease, Wolman disease, acute fatty liver of pregnancy or lipodystrophy; a nutritional cause, such as, for example, malnutrition, total parenteral nutrition, severe weight loss, refeeding syndrome, jejuno-ileal bypass, gastric bypass or jejunal diverticulosis with bacterial overgrowth; consumption or exposure to drugs and toxins, such as, for example, amiodarone, methotrexate, diltiazem, highly active antiretroviral therapy, glucocorticoids, tamoxifen or environmental hepatotoxins; inflammatory bowel disease or HIV.

[0121] In another embodiment of the invention, the lesion is inflammation. In one embodiment where the organ is liver, inflammation may refer to NASH.

[0122] According to the invention, the score obtained at step (c) of the method of the invention is indicative of the presence and/or of the severity of lesions in an organ or in a tissue. In one embodiment of the invention, the score ranges from 0 to 1, and the higher the value of the score, the higher the probability for the subject to have developed lesions.

[0123] In one embodiment, the method of the invention is a method of pathological diagnosis of lesions.

[0124] In one embodiment of the invention, the method of the invention is for diagnosing a disease characterized by the presence of lesions in an organ or tissue. According to this embodiment, the score obtained at step (c) of the method of the invention is a diagnostic score, which means that it is indicative of the presence and/or of the severity of a specific disease, defined as the "diagnostic target". In one embodiment of the invention, the score ranges from 0 to 1, and the higher the value of the score, the higher the probability for the subject to be diagnosed with the diagnostic target.

[0125] Examples of diagnostic targets include, but are not limited to, clinically significant fibrosis and cirrhosis.

[0126] In one embodiment of the invention, the method is for determining an increased risk of complications due to the presence and/or severity of lesions or of the disease, preferably of the diagnostic target. According to this embodiment, the score obtained at step (c) of the method of the invention is a prognostic score, which means that it is indicative of a risk of complications. Examples of complications include, but are not limited to, death, hospitalization, severe impairment of the function of the organ or tissue comprising the lesions, potentially leading to the necessity of a graft of said organ, and the like.

[0127] In one embodiment of the invention, the method of the invention allows a direct assessment of the presence and/or severity of a lesion, or a direct diagnostic of the diagnostic target, i.e. the method leads to a binary diagnostic. In other words, according to this embodiment, the method of the invention usually leads to a dual type response "yes or no": according to the value of the score obtained at step (c), a direct conclusion about the presence and/or severity of a lesion or a disease may be given. For example, according to this embodiment, when the diagnostic target is clinically significant fibrosis, the method of the invention allows determining if the subject is affected or not by clinically significant fibrosis.

[0128] In another embodiment of the invention, the method of the invention leads to the classification of the subject in a class of a classification. For example, when the lesion is fibrosis and the organ is liver, the method of the invention may determine the META VIR F stage or the ISHAK F stage of the subject.

[0129] In another embodiment of the invention, the method of the invention indicates, for the subject, a belonging probability for each class of a classification. For example, when the lesion is fibrosis and the organ is liver, the method of the invention may indicate the probability of the subject to belong to each class of the META VIR F stage or of the ISHAK stage.

[0130] In one embodiment of the invention, the method of the invention is for classifying a subject in a classical classification. Examples of classical classification for liver fibrosis include, but are not limited to, META VIR staging and ISHAK staging.

[0131] In another embodiment of the invention, the method of the invention is for classifying a subject in a classification, whatever said classification is classical or not.

[0132] In one embodiment of the invention, the method for assessing the presence and/or the severity of a lesion in an organ or a tissue of a subject further comprises assessing at least one non-invasive test marker (i.e. markers measured by a non-invasive test). According to one embodiment, the non-invasive test markers are mathematically combined with the two-dimensional image descriptors and/or with the three-dimensional image descriptors.
As used herein, a "Non-invasive diagnostic test" refers to a test for diagnosing, or for assessing the presence and/or severity of a lesion in an organ or tissue or of a disease. In one embodiment, a non-invasive diagnostic test may give a data, or a score, which all correspond within the present invention to a "non-invasive test marker". Such test may use measurement of biomarkers (measured in a sample from the subject, wherein the sample may be a bodily fluid sample, such as, for example, a blood, serum or urine sample, preferably a blood or serum sample), clinical data (i.e. data recovered from external observation of the subject, without the use of laboratory tests and the like), physical data (such as those obtained by the Fibroscan, for example), or scores. In one embodiment, a non-invasive test marker may be a biomarker, a clinical data, or a physical data, or a score.

Examples of non-invasive tests resulting in a score include, but are not limited to, ELF, FibroSpect™, Hepascore, Fibrotest™, FibroMeter™, InflaMeter™, CirrhoMeter™, CombiMeter™, APRI and FIB-4.

Examples of biomarkers include, but are not limited to, glycemia, total cholesterol, HDL cholesterol (HDL), LDL cholesterol (LDL), AST (aspartate aminotransferase), ALT (alanine aminotransferase), AST/ALT, AST.ALT, ferritin, platelets (PLT), AST/PLT, prothrombin time (PT) or prothrombin index (PI), hyaluronic acid (HA or hyaluronate), haemoglobin, triglycerides, alpha-2 macroglobulin (A2M), gamma-glutamyl transpeptidase (GGT), urea, bilirubin, apolipoprotein A1 (ApoA1), type III procollagen N-terminal propeptide (P3NP), gamma-globulins (GBL), sodium (Na), albumin (ALB), ferritine (Fer), glucose (Glu), alkaline phosphatases (ALP), YKL-40 (human cartilage glycoprotein 39), tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), TGF, cytokeratine 18 and matrix metalloproteinase 2 (MMP-2) to 9 (MMP-9), ratios and mathematical combinations thereof.

Examples of clinical data include, but are not limited to, weight, body mass index, age, sex, hip perimeter, abdominal perimeter or height and mathematical combinations thereof, such as, for example, the ratio thereof, such as for example hip perimeter/abdominal perimeter.

Examples of physical methods, such as, for example, physical methods for assessing liver disease include, but are not limited to, medical imaging data and clinical measurements, such as, for example, measurement of spleen, especially spleen length. According to an embodiment, the physical method is selected from the group comprising ultrasonography, especially Doppler-ultrasonography and elastometry ultrasonography and velocimetry ultrasonography (preferred tests using said data are Fibroscan™, ARFI, VTE, supersonic imaging), MRI (Magnetic Resonance Imaging), and MNR (Magnetic Nuclear Resonance) as used in spectroscopy, especially MNR elastometry or velocimetry. Preferably, the data are Liver Stiffness Evaluation (LSE) data or spleen stiffness evaluation. According to a preferred embodiment of the invention, the data from physical methods are issued from a Fibroscan™.

Examples of tests include, but are not limited to ELF, FibroSpect™, APRI, FIB-4, Hepascore, Fibrotest™, FibroMeter™, CirrhoMeter™, CombiMeter™, InflaMeter™.

ELF is a blood test based on hyaluronic acid, P3P, TIMP-1 and age.
APRI is a blood test based on platelet and AST.
FIB-4 is a blood test based on platelet, ASAT, ALT and age.
HEPASCORE is a blood test based on hyaluronic acid, bilirubin, alpha2-macroglobulin, GGT, age and sex.
FIBROTEST™ is a blood test based on alpha2-macroglobulin, haptoglobin, apolipoprotein A1, total bilirubin, GGT, age and sex.
FIBROMETER™ and CIRRHOMETER™ together form to a family of blood tests, the content of which depends on the cause of chronic liver disease and the diagnostic target, and this blood test family is called FM family and detailed in the table below.

<table>
<thead>
<tr>
<th>Virus</th>
<th>ge</th>
<th>Sex</th>
<th>Weight</th>
<th>A2M</th>
<th>HA</th>
<th>PI</th>
<th>PLT</th>
<th>AST</th>
<th>Urea</th>
<th>GGT</th>
<th>ALT</th>
<th>Fer</th>
<th>Glu</th>
</tr>
</thead>
<tbody>
<tr>
<td>FM V 1G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FM V 2G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM V 2G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FM V 3Ga</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM V 3Ga</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Alcohol</th>
<th>ge</th>
<th>Sex</th>
<th>Weight</th>
<th>A2M</th>
<th>HA</th>
<th>PI</th>
<th>PLT</th>
<th>AST</th>
<th>Urea</th>
<th>GGT</th>
<th>ALT</th>
<th>Fer</th>
<th>Glu</th>
</tr>
</thead>
<tbody>
<tr>
<td>FM A 1G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FM A 2G</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**NAFLD** (steatosis)

<table>
<thead>
<tr>
<th>FM S</th>
<th>COMBIMETER™</th>
<th>INFLAMETER™</th>
</tr>
</thead>
</table>

- **FM**: FibroMeter, **CM**: CirrhoMeter,
- **A2M**: alpha-2 macroglobulin, **HA**: hyaluronic acid, **PI**: prothrombin index, **PLT**: platelets, **Fer**: ferritin, **Glu**: glucose
- **a HA may be replaced by GGT**

**COMBIMETER™** is a family of tests based on the mathematical combination of variables of the FM family (as detailed in the Table hereinabove) or of the result of a test of the FM family with FIBROSCAN™ result. In one embodiment, said mathematical combination is a binary logistic regression.

In one embodiment, CombiMeter™ results in a score based on the mathematical combination of physical data from liver or spleen elastometry such as dispersion index from Fibroscan™ such as IQR or IQR/median or median, preferably of Fibroscan™ median with at least 3, preferably at least 4, 5, 6, 7 or more and more preferably of 7 or 8 or 9 biomarkers and/or clinical data selected from the list comprising glycemia, total cholesterol, HDL cholesterol (HDL), LDL cholesterol (LDL), AST (aspartate aminotransferase), ALT (alanine aminotransferase), AST/ALT, AST.ALT, ferritin, platelets (PLT), AST/PLT, prothrombin time (PT) or prothrombin index (PI), hyaluronic acid (HA or hyaluronate), haemoglobin, triglycerides, alpha-2 macroglobulin (A2M), gamma-glutamyl transpeptidase (GGT), urea, bilirubin, apolipoprotein A1 (ApoA1), type III procollagen N-terminal propeptide (P3NP), gamma-globulins (BLG), sodium (Na), albumin (ALB), ferritine (Fer), glucose (Glu), alkaline phosphatases (ALP), YKL-40 (human cartilage glycoprotein 39), tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), TGF, cytokteratine 18 and matrix metalloproteinase 2 (MMP-2) to 9 (MMP-9), diabetes, weight, body mass index, age, sex, hip perimeter, abdominal perimeter or height and the ratio thereof ratios and mathematical combinations thereof.

In one embodiment, CombiMeter™ results in a score based on the mathematical combination of Fibroscan™ median with at least 3, preferably at least 4, 5, 6, 7 or more and more preferably of 7 or 8 or 9 biomarkers and/or clinical data selected from the list comprising glycemia, total cholesterol, HDL cholesterol, LDL cholesterol, AST, ALT, AST/ALT, ferritin, platelets (PLT), AST/PLT, prothrombin time (PT) or prothrombin index (PI), hyaluronic acid (HA or hyaluronate), haemoglobin, triglycerides, alpha-2 macroglobulin (A2M), gamma-glutamyl transpeptidase (GGT), urea, bilirubin, apolipoprotein A1 (ApoA1), type III procollagen N-terminal propeptide (P3NP), gamma-globulins (BLG), sodium (Na), albumin (ALB), ferritine (Fer), glucose (Glu), alkaline phosphatases (ALP), YKL-40 (human cartilage glycoprotein 39), tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), TGF, cytokteratine 18 and matrix metalloproteinase 2 (MMP-2) to 9 (MMP-9), diabetes, weight, body mass index, age, sex, hip perimeter, abdominal perimeter or height and the ratio thereof ratios and mathematical combinations thereof.

In one embodiment, CombiMeter™ results in a score based on the mathematical combination of Fibroscan™ median and at least 3, preferably at least 4, 5, 6, 7 or more and more preferably of 7 or 8 or 9 biomarkers and/or clinical data selected from the list comprising glycemia, total cholesterol, HDL cholesterol, LDL cholesterol, AST, ALT, AST/ALT, ferritin, platelets (PLT), AST, Urea, GGT, Bilirubin (Bili), ALT, Ferritin, Glucose, age, sex and weight.

In one embodiment, CombiMeter™ results in a score based on the mathematical combination of Fibroscan™ median with at least 3, preferably at least 4, 5, 6, 7 or more and more preferably of 7 or 8 or 9 biomarkers and/or clinical data selected from the list comprising glycemia, total cholesterol, HDL cholesterol, LDL cholesterol, AST, ALT, AST/ALT, ferritin, platelets (PLT), AST, Urea, GGT, Bilirubin (Bili), ALT, Ferritin, Glucose, age, sex and weight.

In one embodiment, CombiMeter™ results in a score based on the mathematical combination of Fibroscan™ median with platelets, PI, AST, HA, A2M, sex and age. In another embodiment, CombiMeter™ results in a score based on the mathematical combination of Fibroscan™ median with platelets, PI, AST, HA, A2M, urea, ALT, sex and age.

In one embodiment, CombiMeter™ results in a score based on the mathematical combination of Fibroscan™ median with platelets, PI, AST, HA, A2M, sex and age. In another embodiment, CombiMeter™ results in a score based on the mathematical combination of Fibroscan™ median with platelets, PI, AST, HA, A2M, diabetes and age.

In one embodiment, CombiMeter™ results in a score based on the mathematical combination of Fibroscan™ median with platelets, PI, AST, HA, A2M, diabetes and age. In another embodiment, CombiMeter™ results in a score based on the mathematical combination of Fibroscan™ median with platelets, PI, AST, HA, A2M, diabetes and age.

In another embodiment, CombiMeter™ results in a score based on the mathematical combination of Fibroscan™ median with platelets, PI, AST / ALT, A2M, diabetes and age. In another embodiment, CombiMeter™ results in a score based on the mathematical combination of Fibroscan™ median with a score of CirrhoMeter™, preferably a score of CirrhoMeter2G.

In another embodiment, CombiMeter™ results in a score based on the mathematical combination of Fibroscan™ median with a score of FibroMeter™, preferably a score of FibroMeter2G.

**INFLAMETER™** is a companion test reflecting necro-inflammatory activity including ALT, A2M, PI, and platelets.

**[0139]** In one embodiment, the method for assessing the presence and/or the severity of a lesion in an organ or a tissue of a subject comprises recovering at least one two-dimensional image of said organ or tissue, preferably a histological section image.

**[0140]** In another embodiment, the method for assessing the presence and/or the severity of a lesion in an organ or a tissue of a subject comprises recovering at least one three-dimensional image of said organ or tissue, preferably an image of the entire organ or tissue, more preferably an image recovered by a non-invasive method, such as, for example, tomodensitometry.

**[0141]** In one embodiment, the method for assessing the presence and/or the severity of a lesion in an organ or a tissue of a subject comprises recovering at least one two-dimensional image of said organ or tissue, preferably a histological section image and at least one three-dimensional image of said organ or tissue, preferably an image of the entire organ or tissue, more preferably an image recovered by a non-invasive method, such as, for example, tomoden-
simetry. According to one embodiment, the two-dimensional image descriptors (i.e. descriptors measured on said at least one two-dimensional image) and the three-dimensional image descriptors (i.e. descriptors measured on said at least one three-dimensional image) are mathematically combined in a score.

In one embodiment, the method for assessing the presence and/or the severity of a lesion in an organ or a tissue of a subject further comprises assessing at least one non-invasive test marker as described hereinabove. According to one embodiment, the non-invasive test markers are mathematically combined with the two-dimensional image descriptors and/or with the three-dimensional image descriptors.

Therefore, in some embodiments, the method of the invention may comprise assessing:

- At least one two-dimensional image descriptor;
- At least one two-dimensional image descriptor and at least one non-invasive tests marker;
- At least one three-dimensional image descriptor;
- At least one three-dimensional image descriptor and at least one non-invasive tests marker;
- At least one two-dimensional image descriptor and at least one three-dimensional image descriptor; or
- At least one two-dimensional image descriptor and at least one three-dimensional image descriptors and at least one non-invasive tests marker.

In one embodiment, the diagnostic target is cirrhosis, and the method of the invention comprises mathematically combining the following descriptors in a score: mean of percentage of fibrosis around areas (PCT_NOD), area of stellar fibrosis among the surface of porto-septal regions (AOF_STELLAR_EP), number of bridges (NB_BRIDGE), linearity percentage of the edges (PCT_RECT), LB_LENGTH, fractal dimension of porto-septal fibrosis (DF_FPORT), ratio of peri-sinusoidal fibrosis among the whole fibrosis (RATIO_FPS), length of the organ or fragment thereof (ORGAN_LENGTH), fractal dimension of peri-sinusoidal fibrosis (DF_FPS) and anfractuosity descriptors (native perimeter, smoothed perimeter and ratio between both perimeters).

In another embodiment, the diagnostic target is clinically significant fibrosis, and the method of the invention comprises mathematically combining the following descriptors in a score: bridges thickness (MEAN_THICK_BRIDGE) and linearity percentage of the edges (PCT_RECT) and granularity percentage thereof (ORGAN_GRANULARITY), area of fibrosis in the bridges (AOF_BRIDGE) and fractal dimension of peri-sinusoidal fibrosis (DF_FPS) and anfractuosity descriptors (native perimeter, smoothed perimeter and ratio between both perimeters).

Preferably, said mathematical combination is a linear combination of several descriptors (x,y,...) like a + bx + cy (a, b, c... being the coefficients), preferably a binary logistic regression.

In one embodiment of the invention, the mathematical function is a binary logistic regression, a multiple linear regression or any multivariate statistical analysis.

In one embodiment of the invention, the mathematical combination implies a linear discriminant analysis.

In one embodiment, the diagnostic target is clinically significant fibrosis, and the method of the invention comprises mathematically combining the following descriptors in a score: linearity percentage of the edges (PCT_RECT), mean of percentage of fibrosis around areas (PCT_NOD), area of stellar fibrosis among the total surface of the LB specimen (AOF_STELLAR_TOT), number of bridges (NB_BRIDGE) and bridges thickness (MEAN_THICK_BRIDGE).

Preferably, said mathematical combination is a binary logistic regression.

In another embodiment, the diagnostic target is clinically significant fibrosis, and the method of the invention comprises mathematically combining the following descriptors in a score: bridges thickness (MEAN_THICK_BRIDGE) and linearity percentage of the edges (PCT_RECT).

Preferably, said mathematical combination is a binary logistic regression.

In another embodiment, the diagnostic target is clinically significant fibrosis, and the method of the invention comprises mathematically combining the following descriptors in a score: perimeter of the organ or fragment thereof (ORGAN_PERIMETER), area of fibrosis in the bridges (AOF_BRIDGE), fractal dimension of porto-septal fibrosis (DF_FPORT), ratio of peri-sinusoidal fibrosis among the whole fibrosis (RATIO_FPS), length of the organ or fragment thereof (ORGAN_LENGTH), fractal dimension of peri-sinusoidal fibrosis (DF_FPS) and anfractuosity descriptors (native perimeter, smoothed perimeter and ratio between both perimeters).

Preferably, said mathematical combination is a binary logistic regression.

In one embodiment, the diagnostic target is cirrhosis, and the method of the invention comprises mathematically combining the following descriptors in a score: linearity percentage of the edges (PCT_RECT), granularity percentage thereof (ORGAN_GRANULARITY), fragmentation (INDEX_FRAGMENTATION), mean of percentage of fibrosis around areas (PCT_NOD), area of stellar fibrosis among the surface of porto-septal regions (AOF_STELLAR_EP), and portal distance (DIST_EP_MEAN).

Preferably, said mathematical combination is a binary logistic regression.

In another embodiment, the diagnostic target is cirrhosis, and the method of the invention comprises mathematically combining the following descriptors in a score: mean of percentage of fibrosis around areas (PCT_NOD), area of stellar fibrosis among the total surface of the LB specimen (AOF_STELLAR_TOT), number of bridges (NB_BRIDGE) and bridges thickness (MEAN_THICK_BRIDGE).
fractal dimension of peri-sinusoidal fibrosis (DF_FPS), perimeter of the organ or fragment thereof (ORGAN_PERIMETER).

[0161] Preferably, said mathematical combination is a binary logistic regression.

[0162] In one embodiment, the diagnostic target is NAFLD (non-alcoholic fatty liver disease), preferably NASH (non-alcoholic steatohepatitis), and the method of the invention comprises mathematically combining the following descriptors in a score: fractal dimension of steatosis (DS), fractal dimension of fibrosis (DF) and relative area of steatosis (rAOS).

[0163] Preferably, said mathematical combination is a binary logistic regression.

[0164] In one embodiment, the diagnostic target is definitive NASH, and the method of the invention comprises mathematically combining the following descriptors in a score: luminosity contrast between fibrosis and parenchyma (CONTRAST_FIB_PARENCHYMA), biopsy length (BIOPSY_LENGTH) and area of stellar fibrosis among the total surface of the LB specimen (AOF_STELLAR_TOT).

[0165] Preferably, said mathematical combination is a binary logistic regression.

[0166] In one embodiment, the diagnostic target is borderline and definitive NASH, and the method of the invention comprises mathematically combining the following descriptors in a score: luminosity contrast between fibrosis and parenchyma (CONTRAST_FIB_PARENCHYMA), area of stellar fibrosis among the surface of porto-septal regions (AOF_STELLAR_EP) and area of stellar fibrosis among the total surface of the LB specimen (AOF_STELLAR_TOT).

[0167] Preferably, said mathematical combination is a binary logistic regression.

[0168] In one embodiment, the method of the invention is for predicting the METAVIR stage of a subject, and comprises mathematically combining the following descriptors in a score: linearity percentage of the edges (PCT_RECT), granularity percentage (PCT_GRANULARITY), fragmentation (INDEX_FRAGMENTATION), mean of percentage of fibrosis around areas (PCT_NOD), fractal dimension of porto-septal fibrosis (DF_FPORT), fractal dimension of peri-sinusoidal fibrosis (DF_FPS), ratio of peri-sinusoidal fibrosis among the whole fibrosis (RATIO_FPS) and ratio of bridges among the porto-septal areas (RATIO_BRIDGE).

[0169] Preferably, said mathematical combination is a linear discriminant analysis.

[0170] In one embodiment of the invention, the method of the invention comprises measuring and/or mathematically combining in a score at least 1, 2, 3, 4, 5, 6, 7 or 8 descriptors selected from the list comprising: linearity percentage of the edges (PCT_RECT), granularity percentage (PCT_GRANULARITY), perimeter of the organ or fragment thereof (ORGAN_PERIMETER), fragmentation (INDEX_FRAGMENTATION), mean of percentage of fibrosis around areas (PCT_NOD), fractal dimension of porto-septal fibrosis (DF_FPORT), fractal dimension of peri-sinusoidal fibrosis (DF_FPS), ratio of peri-sinusoidal fibrosis among the whole fibrosis (RATIO_FPS), area of stellar fibrosis among the total surface of the LB specimen (AOF_STELLAR_TOT), area of stellar fibrosis among the surface of porto-septal regions (AOF_STELLAR_EP), number of bridges (NB_BRIDGE), bridges perimeter (MEAN_PERIM_BRIDGE), ratio of bridges among the porto-septal areas (RATIO_BRIDGE), bridges thickness (MEAN_THICK_BRIDGE), mean area of porto-septal regions (MEAN_AO_PORT), length of the organ or fragment thereof (ORGAN_LENGTH), LB_LENGTH, anfractuosity descriptor (native perimeter, smooted perimeter and ratio between both perimeters), fractal dimension of steatosis (DS), fractal dimension of fibrosis (DF), relative area of steatosis (rAOS), portal distance (DIST_EP_MEAN), luminosity contrast between fibrosis and parenchyma (CONTRAST_FIB_PARENCHYMA), and biopsy length (BIOPSY_LENGTH).

[0171] In one embodiment of the invention, the accuracy of the method of the invention corresponds to the percentage of correctly diagnosed or classified patient. Advantageously, the percentage of correctly diagnosed or classified patients is of at least about 80%, preferably at least about 85%, more preferably at least about 90%, and even more preferably at least about 95%.

[0172] In another embodiment of the invention, the accuracy of the method of the invention is assessed by the AUROC of the method. Advantageously, the AUROC is of at least about 0.85, preferably at least about 0.90, more preferably at least about 0.95 and even more preferably at least about 0.99.

[0173] In another embodiment the accuracy of the method of the invention is assessed by measuring the weighted kappa index. Advantageously, the weighted kappa index is of at least about 0.8, preferably of at least about 0.83, more preferably of at least about 0.86.

[0174] The method of the present invention thus presents the following advantages.

[0175] The method of the invention involves the automatic measurement and assessment of the severity of lesions in an organ. Consequently, the method of the invention allows reducing or eliminating subjectivity from diagnosis.

[0176] The method of the invention leads to a score allowing a direct diagnosis or prognosis, without additional step of comparison with a reference database.

BRIEF DESCRIPTION OF THE DRAWINGS

[0177]
Figure 1 is a combination of images showing examples of total fibrosis (A), mask of porto-septal fibrosis (B), porto-septal fibrosis (C) and peri-sinusoidal fibrosis (D) as measured by the method of the invention.

Figure 2 is a combination of images showing focuses at x 20 magnification of total fibrosis (A), mask of porto-septal fibrosis (B), porto-septal fibrosis (C) and peri-sinusoidal fibrosis (D) as measured by the method of the invention.

Figure 3 is a combination of images showing examples of the edge of a non straight liver specimen (A) and a straight liver specimen (B) as measured by the method of the invention.

Figure 4 is a combination of images showing examples of a liver biopsy (LB) mask (A), the skeleton with ramifications (B) and the main skeleton (C) representing its length as measured by the method of the invention.

Figure 5 is a combination of images showing examples of stellar fibrosis around a porto-septal region (A), bridges of fibrosis (B), nodule surrounded by fibrosis (C), the distance measured between the porto-septal regions (D) as measured by the method of the invention.

Figure 6 is a combination of images illustrating the concept of granularity. Examples of fragments (n = 4) of the liver biopsy specimen at the beginning of the study of granularity (A), porto-septal fibrosis on the fragments (B), granules formed by breaking the fragments with porto-septal fibrosis (C) as measured by the method of the invention.

Figure 7 is a combination of images showing examples of small fragments detected for measuring the INDEX_FRAGMENTATION. The total number of fragments is the same for the 2 panels A and B (NB_FRAG = 8). As the area of small fragments is more important in figure A the INDEX_FRAGMENTATION is higher (INDEX_FRAGMENTATION = 67) than in figure B (INDEX_FRAGMENTATION = 35).

Figure 8 is a bean plot of the distribution of the CSF prediction (on Y axis) as a function of METAVIR staging (X axis) in the 416 patients of the MALAH 1 population. The grey filled curve is a kernel density estimate. The small grey lines represent individual data values. The large horizontal grey line shows the chosen threshold and the dotted black line corresponds to the overall median.

Figure 9 is a graph showing the distribution of the logistic function for the F4 prediction (Y axis) as a function of patient values ranked in increasing value (X axis) in the 416 patients of the MALAH 1 population. The horizontal lines depict the different thresholds. Triangle dots correspond to the original METAVIR F4 stage values whereas the white circle dots correspond to the original METAVIR stages less than F4. The black points mark patient slides with significant discordance (a difference of two stages or more between original Metavir evaluation and its prediction).

Figure 10 is a graph showing the distribution of the METAVIR stage prediction by linear discriminant analysis (LDA; Y axis) as a function of the METAVIR stages (on X axis) in the 416 patients of the MALAH 1 population. The vertical lines are drawn according to the proportion of original METAVIR stage values. On the Y axis, points are drawn with respect to the predicted stage. Their order follows their position in the dataset.

Figure 11 is a histogram showing the agreement between the prediction of the Metavir (on Y axis) and the Metavir stages evaluated by an expert (on X axis) in the 416 patients of the MALAH 1 population. The heights of the boxes reflect the proportion of the prediction stages for the expert stage.

Figure 12 is a histogram showing the distribution of NASH diagnosis as a function of intervals 95% predictive values by NASH score.

Figure 13 is a combination of graphs related to the NASH score. (A) deciles of NASH score (X axis) plotted against the proportion of NASH diagnosis (Y axis). (B) box plots of NASH score as a function of 95% predictive values and NASH diagnosis.

Figure 14 is a combination of 4 TDM images of the liver, corresponding to 4 consecutive slices (A, B, C and D) spaced 10 mm.

Figure 15 is a combination of illustrations showing a slice of TDM image (A), the mask of the liver and spleen (B), and the edges of the liver and spleen (C).
Figure 16 is a combination of illustrations showing a slice of TDM image (A) and a zoom on the irregular edges with nodules (B) (see arrows).

Figure 17 is a combination of illustrations showing a thresholded slice of TDM image with a box surrounding the liver (A), the mask of the box (B) and the black pixels corresponding to the fat in the box (C).

Figure 18 is a combination of illustrations showing examples of angles detected for the measure of the edges angularity in the liver of a healthy patient (F0) or in a cirrhotic liver (F4).

Figure 19 is a combination of illustrations showing examples of angles detected for the measure of the edges angularity in the liver of a healthy patient (F0) or in a cirrhotic liver (F4).

Figure 20 is an illustration showing the edge smoothing liver used for measuring the ratio between the 2 perimeters and for evaluating the indentation of the liver.

EXAMPLES

[0178] The present invention is further illustrated by the following examples.

Example 1: Automatic measurement of lesions in a histological image.

METHODS

Study design

[0179] The morphometric diagnosis by automated morphometry was designed to diagnose clinically significant fibrosis (CSF), cirrhosis and Metavir F stages. The diagnostic models were developed in the derivation population. These results were validated by using two kinds of population:

- Populations with reference Metavir staging by expert to validate the diagnostic accuracy of diagnostic models based on automated morphometry.
- Population with Metavir staging performed by a first line pathologist to compare the diagnosis made by automated morphometry with that performed in real life conditions.

[0180] The conditions of liver biopsy specimens were the same in all populations. Especially, specimen lengths were the same and staining and morphometry performed by the same engineer were made centrally in the HIFIH laboratory.

Populations

Derivation population

[0181] 416 patients with chronic viral hepatitis C and a length of digitized biopsy ≥ 20 mm for stages F0 to F3 and ≥ 12.1 mm for F4 were included (18 F0, 169 F1, 116 F2, 59 F3, 54 F4).

Validation populations

[0182] Fibrosys population included 54 patients with chronic viral hepatitis C. Liver biopsy was performed at week 0 and repeated at week 96. These two subsets were considered as different populations to avoid data redundancies. Liver interpretation was made by a single expert.

[0183] Vindiag 10 population included 83 patients with chronic viral hepatitis C having a baseline liver biopsy. Liver
interpretation was made by a single expert.

Fibrostar population included 285 patients with chronic viral hepatitis C having a baseline liver biopsy. Liver interpretation was made by different pathologists with various expertise corresponding to the initial diagnosis as performed in clinical practice.

Liver specimen

All LB were taken by needle through transcostal route, formalin-fixed, included in paraffin blocks and stained with picro-sirius red. This staining highlights the fibrosis in red, healthy tissue in yellow/orange and steatosis appears in white (i.e. optically empty). We aimed at measuring both fibrosis and steatosis. The specimen slides were then fully scanned with an Aperio digital slide scanner (Scanscope CS System, Aperio Technologies, Vista CA 92081, USA) image processor that provided high quality 30,000 x 30,000 pixel images at a resolution of 0.5 μm/pixel (magnification x 20). In order to facilitate sharing and storage of these images, they were compressed using JPEG2000 software with a quality Q = 70. Thus, a slide with 16,000 x 22,000 pixels was decreased from 1 GB (before compression) to 30 MB.

Each virtual slide was analyzed to obtain a variety of parameters describing lesions such as area of fibrosis, fractal dimension ... The combination of all these morphometric data allowed us to automatically diagnose CSF, F4 and METAVIR stage. Then, they were compared to those evaluated by the pathologist.

Classical morphometry

A mask of the biopsy is automatically created (MASK_{LB}) after detecting the white background of the image so that it is not taken into account in the analysis. An operator manually cleans the slide to remove the various artefacts present such as folds, dust, blood vessels, biliary tracts... All these artefacts are removed from MASK_{LB}.

Area and fractal dimension of fibrosis and steatosis

First, a fuzzy generalized classification (Ménard et al, Pattern recognition, 2002) process allows the merging of pixel intensities into three classes (fibrosis, healthy tissue, white areas) using the minimization of an original energy function. S_{FIB} is the threshold of the fibrosis class and S_{W} the threshold of the white class. Then, a specifically-developed expert system (Roullier et al, Conf Proc IEEE Eng Med Biol Soc, 2007:5575-5578) was applied on the previously obtained white-labelled areas to extract steatosis vacuoles and to eliminate blood vessels and biliary tracts (that had characteristics close to those of macro vesicles of steatosis).

The expert system rules are based on the size of the regions (very small areas, considered as noise, are eliminated), the neighborhood regions (vessels surrounded by fibrosis are eliminated), the circularity of the region (4π *area/perimeter^2) (non-round regions, e.g., biliary tracts, were eliminated), the Hough transform of the region (allowing the detection and retention of vesicle aggregates), and a statistical texture parameter (heterogeneous regions, e.g. blood vessels, were eliminated). The measure of the area of fibrosis (AOF) or steatosis (AOS) is equal to the ratio of pixels of fibrosis or steatosis divided by the number of pixels in the studied area:

$$AOF = \frac{Pix_{FIB}}{Pix_{MASK_{LB}}} \times 100$$

$$AOS = \frac{Pix_{STEA}}{Pix_{MASK_{LB}}} \times 100$$

where $Pix_{FIB}$ is the number of fibrosis pixels; $Pix_{STEA}$ is the number of steatosis pixels; and $Pix_{MASK_{LB}}$ is the number of pixels of the study area.

The "box-counting" method (Moal et al, Hepatology, 2002, 36:840-849) has been extensively used for measuring the fractal dimension of many histologic objects as a complexity index. The box-counting method provides the fractal dimension of Kolmogorov (D). The technique has been reported in details for biological structures.

Briefly, a grid of square boxes (with € pixels as the side length) resembling a chessboard was superimposed over the histologic image of threshold fibrosis. Boxes intersecting with collagen fibers were counted. Another chessboard grid was then used to cover the entire surface of the microscopic field. Thus, the total number (N) of boxes of sides (€) required to completely cover the collagen fibers reflects the perimeter examined with the scale ratio €. This step was repeated with € varying until a size of 14 pixels, and data were plotted on a log-log graph (i.e., log [N] against log[€]). The relationship between points was measured by linear regression analysis using the least square method; the slope D of the regression line corresponds to the fractal dimension D. We did the same measurement for the fractal dimension
of steatosis by using the images showing steatosis. We called $D_F$ and $D_S$ the fractal dimension of fibrosis and steatosis, respectively.

**Area and fractal dimension of porto-septal and peri-sinusoidal fibrosis**

[0192] The AOF measured throughout the LB specimen does not distinguish the two kinds of fibrosis which are observed on the slide (Figures 1 and 2). Fibrosis can start in the centro-lobular region (alcoholic liver disease) and/or in the periphery of the lobule or around the portal tracts (viral liver disease). This fibrosis grows gradually to form bands of fibrosis, or septa, called septal fibrosis. This septal fibrosis is extended between the portal tracts or between the portal tracts and the centro-lobular region. The cirrhosis stage occurs when these different septa entirely surround hepatocytes. When pathologists are assessing the Metavir stage, their judgment is based on the porto-septal fibrosis. The other form of fibrosis is located between the rows of hepatocytes and sinusoids, the equivalent of the capillary in the liver, i.e. in the intercellular space where there are many liver metabolic exchanges. This is called the peri-sinusoidal fibrosis. Although it is not taken into account in the fibrosis scores in clinical use, this fibrosis is important because it has a key role in the genesis of liver failure and portal hypertension.

[0193] Consequently, we developed a mask detection of porto-septal regions ($\text{MASK}_\text{PORT}$, Figures 1B and 2B) which allows us to distinguish these two types of fibrosis (porto-septal and peri-sinusoidal fibrosis). The creation of this mask requires a large number of morphometric treatments (regarding erosions, dilations, the size of fibrosis areas...) which involves a long computing time and requires a lot of memory to process the data. This is the reason why we reduced the image dimensions. $\text{IM}_{\text{COL}}$ is the color image of the LB specimen resized with a scale factor $R_{\text{SCALE}} = 4$. $\text{IM}_{\text{GREEN}}$ (the green component of $\text{IM}_{\text{COL}}$) is thresholded by $S_{\text{FIB}}$ in order to get a binary image of fibrosis ($\text{IM}_{\text{FIB}}$). Peri-sinusoidal fibrosis lies between the rows of hepatocytes; therefore, it is sufficient to eliminate it by detecting the hepatocytes which have the intensity of healthy tissue. Concerning veins and vessels, we determined that if their diameter was less than 200 $\mu$m and if the fibrosis around was small compared to their size, they are not considered in the $\text{MASK}_\text{PORT}$. Dilatations and erosions are applied on $\text{IM}_{\text{FIB}}$ in order to obtain compacted regions to study. Porto-septal regions have a lot of fibrosis and therefore the elements of fibrosis with large areas are considered in the $\text{MASK}_\text{PORT}$. The fractal dimension of fibrosis into these regions is also a criterion to determine if it is in $\text{MASK}_\text{PORT}$. Thin regions (small ratio between the perimeter of the area and its surface) with nodes (interconnection points in fibrosis filaments) are a sign of branched forms as observed in peri-sinusoidal fibrosis and are thus not considered as porto-septal fibrosis.

[0194] Finally, we obtained $\text{MASK}_\text{PORT}$ that separate peri-sinusoidal fibrosis from porto-septal fibrosis. The lobular region is the region of the LB without porto-septal fibrosis. We measure the area and the fractal dimension of porto-septal fibrosis ($\text{AO}_\text{FPORT}$ and $\text{DF}_\text{FPORT}$), the area and fractal dimension of peri-sinusoidal fibrosis ($\text{AO}_\text{FPS}$ and $\text{DF}_\text{FPS}$), the area of lobular peri-sinusoidal fibrosis ($\text{AO}_\text{FPS}_\text{LOB}$) and the ratio of peri-sinusoidal fibrosis among the whole fibrosis ($\text{RATIO}_\text{FPS}$) as follows:

$$\text{AO}_\text{FPORT} = \frac{\text{Pix}_\text{PORT}}{\text{Pix}_\text{MASK}_\text{LB}} \times 100$$

$$\text{AO}_\text{FPS} = \frac{\text{Pix}_\text{FPS}}{\text{Pix}_\text{MASK}_\text{LB}} \times 100$$

$$\text{AO}_\text{FPS}_\text{LOB} = \frac{\text{Pix}_\text{FPS}}{\left(\text{Pix}_\text{MASK}_\text{LB} - \text{Pix}_\text{Mask}_\text{Port}\right)} \times 100$$

$$\text{RATIO}_\text{FPS} = \frac{\text{Pix}_\text{FPS}}{\text{Pix}_\text{FIB}_\text{TOT}} \times 100$$

where $\text{Pix}_\text{PORT}$ is the number of pixels of porto-septal fibrosis; $\text{Pix}_\text{FPS}$ is the number of pixels of peri-sinusoidal fibrosis; $\text{Pix}_\text{MASK}_\text{LB}$ is the number of pixels of the total area of the LB specimen; $\text{Pix}_\text{Mask}_\text{Port}$ is the number of pixels of the porto-septal area; and $\text{Pix}_\text{FIB}_\text{TOT}$ is the number of pixels representing all the fibrosis (porto-septal and peri-sinusoidal fibrosis).

[0195] Table 1 resumes all these classical morphometric measurements.

<table>
<thead>
<tr>
<th>Lesions</th>
<th>Lesion measurements</th>
<th>Descriptors (abbreviation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Area of fibrosis and fractal dimension of whole fibrosis</td>
<td>$\text{AOF} / D_F$</td>
<td></td>
</tr>
</tbody>
</table>
The analysis of the edges of the LB specimen (Figure 3) is an important descriptive factor to consider for METAVIR staging. Indeed, the shape of the LB specimen changes according to the METAVIR stages, the edges are very straight in low stages (F0, F1, F2) whereas they tend to become more and more curved and irregular in the high stages (F3, F4). That is why we measured automatically the fractal dimension (DF_EDGE) and the linearity percentage (PCT_RECT) of the edges on the LB specimen. At first, we detect the edges of the fragments on the LB specimen and, thanks to this mask (MASKEDGE), we combine two methods to optimize the detection of straight edges. Method 1 consists to apply the Hough transform to detect straight lines on MASKEDCE. The measurement of the Hough transform is well known in the domain of image processing to detect shapes (Duda et al, Comm ACM, 1972, 15:11-15). This gives a mask called MASKHOUGH containing only the edges of the mask detected as straight by the Hough transform. Method 2 consists to create a straight mask MASKRECT from the edge mask (MASKEDGE). For this, we first detect the corners with a Harris detector (Harris et al, Proceedings of the 4th Alvey Vision Conference, 1988:147-151) and then we keep the edge points separated by a sampling step = 2.4 mm. The lines between all these points are drawn and we finally obtained a theoretical straight mask. MASKRECT represents the edges of MASKEDGE that are in common with this theoretical straight mask.

Thanks to a combination of the 2 masks, we obtained a MASKRECTCOMB (MASKRECTCOMB = MASKHOUGH + MASKRECT). MASKRECTCOMB thus contains all the straightest edges of the LB specimen. They determine the following formula:

\[
PCT\_RECT = \frac{\text{Pix}_{\text{MaskRectComb}}}{\text{Pix}_{\text{MaskEdge}}} \times 100.
\]

where PixMaskRectComb is the number of pixels of MASKRECTCOMB; and PixMaskEdge is the number of pixels of MASKEDGE.

Measure of the LB specimen length (LB_LENGTH)

The pathologists consider that the LB specimen length must be higher than 15 or 20 mm to be representative. Usually, it is manually measured directly on the slide but this is not very precise because the LB specimen is not always straight. So, we decided to measure it automatically (LB_LENGTH) on the virtual slide. We use the mask obtained after the elimination of the artefacts (MASKedg) and we apply a morphometric operation (skeletonization) which gives us a skeleton of the LB. Then the small ramifications are removed in order to keep the main skeleton (MASKSKELETON) that represents the LB’s length (Figure 4).

\[
LB\_LENGTH = \text{Pix}_{\text{LB\_SKELETON}} \times \text{IM}\_\text{Resolution} \times R\_\text{SCALE}.
\]

wherein PixLB_SKELETON is the number of pixels that represent the LB specimen length on MASKLB, IMResolution is the resolution of the scanned image (0.5 μm) and RSCALE = 4 is the scale factor used to resize the image.
Measure of LB.PERIMETER and LB.AREA

[0199] We measure automatically the perimeter and the area of the LB (LB.PERIMETER, LB.AREA). We detect the edges of the fragments on the LB specimen and, thanks to this mask (MASKEDGE), the perimeter is calculated as follow:

\[
LB\_PERIMETER = Pix_{\text{MaskEdge}} \times IM_{\text{Resolution}} \times R_{\text{SCALE}}.
\]

\[
LB\_AREA = Pix_{\text{MASK\_LB}} \times IM_{\text{Resolution}}^2 \times R_{\text{SCALE}}^2.
\]

wherein \(Pix_{\text{MaskEdge}}\) is the number of pixels of \(\text{MASKEDGE}\); \(Pix_{\text{MASK\_LB}}\) is the number of pixels of the total area of the LB specimen; \(IM_{\text{Resolution}}\) is the resolution of the scanned image (0.5 \(\mu\text{m}\)) and \(R_{\text{SCALE}} = 4\) is the scale factor used to resize the image.

Measure of stellar fibrosis (AOF.STELLAR_TOT, AOF.STELLAR_EP, AOF.STELLAR_LOB, MEAN_STELLAR_PORT and MEAN_AO_PORT)

[0200] The main feature to differentiate stage of fibrosis F0 from stage F1 and higher stages is the presence of star-branched fibrosis around porto-septal regions (Figure 5A). Indeed, fibrosis that we called stellar fibrosis starts to appear at the stage F1 around the portal tracts. These are small and fine fibrils around a more dense area. Therefore, it is interesting to automatically quantify this stellar fibrosis among the total surface of the LB specimen (AOF.STELLAR_TOT), among the surface of porto-septal regions (AOF.STELLAR_EP) and among the surface of lobular regions (AOF.STELLAR_LOB). We also used the number of porto-septal regions (NB_PORT) to measure the mean area of stellar fibrosis (MEAN_STELLAR_PORT) and the mean area of porto-septal regions (MEAN_AO_PORT).

[0201] To make this measurement, we detect fibrosis in a distance of 100 \(\mu\text{m}\) around the porto-septal regions of MASKPORT. In order to differentiate stellar fibrosis from peri-sinusoidal fibrosis and concentrated fibrosis in the portal tracts, we combine several morphometric operations (successive erosions and dilations) which enable to only keep the thin fibrils of fibrosis connected to the porto-septal regions. Stellar fibrosis is measured with the following formulas:

\[
AOF\_STELLAR\_TOT = \frac{Pix\_Fib\_Stellar}{Pix_{\text{MASK\_LB}}} \times 100
\]

\[
AOF\_STELLAR\_EP = \frac{Pix\_Fib\_Stellar}{Pix_{\text{Mask\_Port}}} \times 100
\]

\[
AOF\_STELLAR\_LOB = \frac{Pix\_Fib\_Stellar}{(Pix_{\text{MASK\_LB}} - Pix_{\text{Mask\_Port}})} \times 100
\]

\[
MEAN\_STELLAR\_PORT = \frac{Pix\_Fib\_Stellar}{NB\_PORT}
\]

\[
MEAN\_AO\_PORT = \frac{Pix\_Mask\_Port}{NB\_PORT}
\]

where \(Pix\_Fib\_Stellar\) is the number of pixels detected as stellar fibrosis; \(Pix_{\text{MASK\_LB}}\) is the number of pixels of the total area on the LB specimen; \(Pix\_Mask\_Port\) is the number of pixels of the porto-septal area in \(\text{MASKPORT}\); and \(NB\_PORT\) is the number of porto-septal regions in \(\text{MASKPORT}\).

Measure of bridging fibrosis (NB_BRIDGE, RATIO_BRIDGE, AOF_BRIDGE, MEAN_SURF_BRIDGE, MEAN_PERIM_BRIDGE, MEAN_THICK_BRIDGE)

[0202] Bridging fibrosis fibers occur at the METAVIR stage F2. We use the term bridges when two portal tracts are interconnected (Figure 5B). A bridge is defined as a structure lying between two thick elements. In general, pathologists consider that if there is a ratio of more than 50% of bridges, the METAVIR stage will be higher than F2. It is therefore
important to measure the number of bridges (NB_BRIDGE), their ratio among the porto-septal areas (RATIO_BRIDGE), the area of fibrosis in the bridges (AOF_BRIDGE) and the bridges thickness (MEAN_THICK_BRIDGE) which is obtained thanks to their perimeter (MEAN_PERIM_BRIDGE) and their surface (MEAN_SURF_BRIDGE). For each porto-septal region in MASK_Port, we apply morphometric operations such as high erosion followed by a small dilation. The aim is to observe a separation of the structures which determines the presence of bridges. At the end of the morphometric operations, a studied area with at least two elements is considered as a bridge and added in the MASK_Bridge. We obtain the following parameters:

\[
\text{NB_BRIDGE} \text{ is the number of bridges in } \text{MASK_BRIDGE}
\]

\[
\text{RATIO_BRIDGE} = \frac{\text{Pix_Mask_Bridge}}{\text{Pix_Mask_Port}} \times 100
\]

\[
\text{AOF_BRIDGE} = \frac{\text{Pix_Fib_Bridge}}{\text{PixMASK_LB}} \times 100
\]

where Pix_Mask_Port is the number of pixels in MASK_Port; Pix_Mask_Bridge is the number of pixels in MASK_Bridge; Pix_Fib_Bridge is the number pixels of fibrosis in the bridges; and PixMASK_LB is the number of pixels of the total area on the LB specimen.

\[
\text{MEAN_THICK_BRIDGE} = \frac{\text{MEAN_SURF_BRIDGE}}{\text{MEAN_PERIM_BRIDGE}} \times 100
\]

where MEAN_SURF_BRIDGE is the mean of pixels representing the surface of bridges and MEAN_PERIM_BRIDGE is the mean of pixels representing the perimeter of bridges.

Measure of granularity (PCT_GRANULARITY)

[0203] The architecture of liver fibrosis is modified in high METAVIR stages. Indeed, the fibrous bridges can disorganize the LB specimen (Figure 6). The measure of the granularity percentage (PCT_GRANULARITY) aims at quantifying this destructuration of the LB specimen by porto-septal tracts.

[0204] First, we count the number of fragments (NB_FRAG) in the mask obtained after the elimination of the artefacts (MASK_LB). Then, we use the porto-septal mask (MASK_Port) in which we applied several dilations in order to extend the porto-septal areas. We subtract MASK_Port from MASK_LB in order to only observe the granules formed by breaking the fragments. Nb_Granules is the number of granules. PCT_GRANULARITY is the ratio between the number of fragments without destructuration and the number of granules obtained in these fragments after destructuration by porto-septal areas:

\[
\text{PCT_GRANULARITY} = 100 - \left(\frac{\text{NB_FRAG}}{\text{Nb_Granules}} \times 100\right)
\]

Measure of fragmentation (INDEX_FRAGMENTATION)

[0205] A LB specimen is sometimes fragmented. It depends on the METAVIR stage, especially for the F4 stage where the LB specimen could contain several small fragments. So, the measure of the fragmentation index can be useful for the high fibrosis stages with a little PCT_GRANULARITY because of a numerous fragmentation.

[0206] As for measuring PCT_GRANULARITY, we use MASK_LB. We detect on this mask the small fragments (Figure 7) in order to obtain MASK_FRAG_SMALL. We consider as small a fragment with a surface under 2 mm² or a bigger fragment with a surface under 3 mm² but with a circularity up to 0.7. The fragmentation index is the ratio between the surface of small fragments detected and the total surface of the LB specimen:

\[
\text{INDEX_FRAGMENTATION} = \frac{\text{Pix_Mask_Frag_Small}}{\text{Pix_Mask_Frag}} \times 100
\]

where Pix_Mask_Frag is the number of pixels in MASK_LB and Pix_Mask_Frag_Small is the number of pixel in...
The stage F4, also known as cirrhosis, is mainly characterized by the formation of nodules (Figure 5C). These nodules are the result of the disruption of fibrosis that circles regions of hepatocyte tissue (parenchyma). So, a nodule is a circular and non-fibrotic (without fibrous septa inside) area surrounded by fibrosis.

The process is the same as the measure of the \( PCT\_GRANULARY \) applying \( MASK\_PORT \) on \( MASK\_LB \) to study the granules obtained. We only keep the granules if they are circular. The nodules are not always perfectly round, that is why we choose a circularity threshold of 0.45. Among these round granules, we keep those that have at least 30% of fibrosis around (30% of the external border). We finally obtained a mask with regions tending towards nodularity (\( MASK\_KNOD \)). Nodules were considered as definitive when \( PCT\_GRANULARY \) was \( \geq 80\% \). We use the following formulas:

\[
PCT\_NOD = \text{mean of percentage of fibrosis around areas in } MASK\_NOD.
\]

\[
NB\_NOD = \text{number of nodules in } MASK\_NOD \text{ with more than 80\% of fibrosis around.}
\]

We also measured the number of nodules in \( MASK\_NOD \) with more than 30% of fibrosis around (\( NB\_NOD\_30 \)). The process is the same as the measure of \( NB\_NOD \) but this time we keep the nodules in \( MASK\_NOD \) with more than 30% of fibrosis around.

\[
NB\_NOD\_30 = \text{number of nodules in } MASK\_NOD \text{ with more than 30\% of fibrosis around.}
\]

As mentioned above, the location of portal tracts tends to be heterogeneous in the higher fibrosis stages. So they are no longer distributed regularly and are closer to each other. It seems therefore interesting to measure the average distance between these porto-septal regions (Figure 5D). \( NB\_FRAG \) is the number of fragments in \( MASK\_LB \), \( Nb\_EP\_n \) is the number of porto-septal regions present on the fragment \( n \) (\( n \) lies between 1 and \( NB\_FRAG \)). For each \( n \) fragment, we measure the minimum distance \( Dmin\_n \) between all porto-septal regions present on \( MASK\_PORT \). \( Dmoyn \) is the average distance between regions on the porto-septal fragment \( n \).

\[
Dmoyn = Dmin\_n / (Nb\_EP\_n - 1).
\]

The average distance between porto-septal regions for all fragments is called \( DIST\_EP\_MEAN \):

\[
DIST\_EP\_MEAN = (Dmoyn\_1 + Dmoyn\_2 + ... + Dmoyn\_NB\_FRAG) / NB\_FRAG.
\]

Table 2 resumes all these new morphometric measurements.

<table>
<thead>
<tr>
<th>Lesions</th>
<th>Descriptor (abbreviation)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Directly related to fibrosis:</strong></td>
<td></td>
</tr>
<tr>
<td>Stellar fibrosis</td>
<td>AOF_ STELLAR_TOT</td>
</tr>
<tr>
<td></td>
<td>AOF_ STELLAR_EP</td>
</tr>
<tr>
<td></td>
<td>AOF_ STELLAR_LOB</td>
</tr>
<tr>
<td></td>
<td>MEAN_ STELLAR_PORT</td>
</tr>
</tbody>
</table>
Quality of the staining

The performance of our measures depends on the quality of the staining (coloration) of the LB. Indeed, with a pale color of fibrosis, the detection could miss some porto-septal regions, and consequently we could underestimate the classification (CSF, F4 and Metavir). Usually, the pathologist excluded the cases with a poor coloration. That is why we decided to automatically detect the LB to be excluded due to poor coloration. All the measures of intensity luminosity are applied on the three components of the image (RGB: Red, Green and Blue). The luminosity intensity of the LB is calculated by averaging all this pixel intensity and we obtain a mean intensity for each component: $I_{lbR}$ (the mean intensity of the LB on the red component), $I_{lbG}$ and $I_{lbB}$. We do the same for the intensity of fibrosis ($I_{fibR}$, $I_{fibG}$, and $I_{fibB}$) and for the parenchyma ($I_{parenchymaR}$, $I_{parenchymaG}$, and $I_{parenchymaB}$).

The quality of the coloration is also bad if the fibrosis intensity is close to the intensity of the parenchyma or the LB. Thus, there is a weak contrast between the fibrosis and the parenchyma or LB. We developed a measure of these contrast as follows:

$\text{Contrast}_{\text{Fib,Parenchyma}} = \sqrt{(I_{parenchymaR} - I_{fibR})^2 + (I_{parenchymaG} - I_{fibG})^2 + (I_{parenchymaB} - I_{fibB})^2}$

$\text{Contrast}_{\text{Fib, LB}} = \sqrt{(I_{lbR} - I_{fibR})^2 + (I_{lbG} - I_{fibG})^2 + (I_{lbB} - I_{fibB})^2}$

Table 3 resumes all these measurements of luminosity intensity.

Table 3. New measurements of luminosity intensity describing the quality of the coloration of the LB specimen (n=11).

<table>
<thead>
<tr>
<th>Luminosity characteristic</th>
<th>Descriptor (abbreviation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibrosis luminosity</td>
<td>$I_{fibR}$ $I_{fibG}$ $I_{fibB}$</td>
</tr>
<tr>
<td>Parenchyma luminosity</td>
<td>$I_{parenchymaR}$ $I_{parenchymaG}$ $I_{parenchymaB}$</td>
</tr>
</tbody>
</table>
We used a classical two-step modeling strategy: a building step on all the data and an external validation step using two other datasets. After a first quick univariate study of all variables on the whole set of original data (416 slides) and a second analysis for each of the five METAVIR stages, we decided to perform bivariate analysis on quantitative variables using Spearman's rank correlation coefficient ($r_s$) because (i) the normality assumption was not often fulfilled and (ii) some subsample had a small number of slides. Since regression techniques work better when variables are not strongly correlated, we partitioned all the original variables into clusters that were composed of variables that were altogether highly correlated ($r_s > 0.8$) and we then chose the most relevant variables for each cluster, thus reducing the 31 original variables to a set of 25 variables that were not too correlated. For the two binary outcomes (CSF and cirrhosis) we looked for the best binary logistic regression (BLR) model whereas for the 5-valued ordinal outcome METAVIR staging we looked for the best discriminant model using linear, quadratic, flexible, mixture techniques and other methods of logit analysis for ordered categories. All analyses were realized using the R software (Team RDC, available from http://www.R-project.org).

After a thorough comparison of the outputs of the numerous programs for selecting the best variables (using both forward selection, backward elimination, and best subset selection procedures), we were able to end up for each of the three diagnostic targets with a statistical model that can be considered the best of all models, taking into account the performance of the model and the minimality of the number of variables. It has to be noted that for the ordinal variable METAVIR staging, the best model was found using a linear discriminant analysis method (LDA).

For the LDA model, we tested several imputations methods to deal with the probabilities of each ordinal value including maximum probability value imputation, class weighted imputation, two-stage values such as $F_{x/y}$ or $F_{x/y}$ (the bigger value indicating an increased preference for the stage)… before computing also concordance and classification rates using here weighted distances between the stages. Finally, we decided to keep the standard method maximum probability value imputation since it gives good results without the introduction of arbitrary thresholds.

For each of the computed models, the misclassification error was introduced as a new binary value and two new LBR regressions were performed using this value as target (i) with all the original 25 retained variables, (ii) using only the selected descriptors of the model, in order to analyze the influence of the variables on the misclassification. Since we knew the original value of METAVIR stage for the slides, it was possible to analyze the severe misclassification errors (discordance of more than one stage).

The performance of a model is well known to be overestimated when evaluated on the data that led to the model (optimism bias). So we checked the three models against two other populations. The first one, called here FIBROSYS, used slides of 54 patients at two distinct periods, week 0 (W0) and week 96 (W96). The second file of data for the external validation, VINDIAG10, was composed of 83 patient slides selected from a cohort respecting the same conditions as the original data (METAVIR stage F4 or a length of digitized biopsy $\geq 20$ mm). Table 4 shows the distribution of the METAVIR stages for all the datasets.

<table>
<thead>
<tr>
<th>Luminosity characteristic</th>
<th>Descriptor (abbreviation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall luminosity (of specimen)</td>
<td>ILbR</td>
</tr>
<tr>
<td>Luminosity contrast between fibrosis and parenchyma</td>
<td>Contrast_Fib_Parenchyma</td>
</tr>
<tr>
<td>Luminosity contrast between fibrosis and specimen (overall luminosity)</td>
<td>Contrast_Fib_Lb</td>
</tr>
</tbody>
</table>

Table 4 shows the distribution of the METAVIR stages for all the datasets.
RESULTS

Derivation population

CSF prediction

The best BLR model includes 5 descriptors among those described previously: AOF_STELLAR_TOT, MEAN_THICK_BRIDGE, NB_BRIDGE, PCT_NOD, and PCT_RECT. The threshold value, "a priori" set to 0.5, was kept because of the prevalence of CSF (55%) and the good specificity and sensitivity of the associated model. With this threshold, we correctly classified almost 87.3% of the patients and we obtain an AUROC of 0.96. In the discordance matrix, we have the following results: 165 true-negative (TN), 198 true-positive (TP), 22 false-positive (FP) and 31 false-negative (FN). The results obtained (Figure 8) confirm that this is a very good model to predict CSF. Table 5 gives the overall results of performance for the original dataset (MALAH 1) and Table 5b provides the model coefficients.

Table 4. Distribution of the METAVIR stages for the four datasets (populations).

<table>
<thead>
<tr>
<th>Population</th>
<th>METAVIR stages</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>F0</td>
</tr>
<tr>
<td>MALAH 1</td>
<td>18</td>
</tr>
<tr>
<td>FIBROSYS W0</td>
<td>0</td>
</tr>
<tr>
<td>FIBROSYS W96</td>
<td>0</td>
</tr>
<tr>
<td>VINDIAG 10</td>
<td>2</td>
</tr>
</tbody>
</table>

Table 5. Overall results for the CSF prediction model. Correct classification rate using an a priori 0.5 threshold value.

<table>
<thead>
<tr>
<th>Population</th>
<th>Patients (n)</th>
<th>AUROC</th>
<th>Correctly classified (%)</th>
<th>Discordance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Value</td>
<td>LWR</td>
<td>UPR</td>
<td></td>
</tr>
<tr>
<td>MALAH 1</td>
<td>416</td>
<td>0.957</td>
<td>0.940</td>
<td>0.973</td>
</tr>
<tr>
<td>FIBROSYS W0</td>
<td>54</td>
<td>0.857</td>
<td>0.724</td>
<td>0.990</td>
</tr>
<tr>
<td>FIBROSYS W96</td>
<td>54</td>
<td>0.895</td>
<td>0.787</td>
<td>1.003</td>
</tr>
<tr>
<td>VINDIAG 10</td>
<td>83</td>
<td>0.880</td>
<td>0.804</td>
<td>0.955</td>
</tr>
</tbody>
</table>

Table 5b. Coefficients of the binary logistic regression for CSF prediction.

<table>
<thead>
<tr>
<th>#</th>
<th>Variable</th>
<th>Lower</th>
<th>Coefficient</th>
<th>Upper</th>
<th>Std. error</th>
<th>z-value</th>
<th>Prob.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AOF_STELLAR_TOT</td>
<td>15.1400</td>
<td>22.0255</td>
<td>29.7866</td>
<td>3.7235</td>
<td>5.9153</td>
<td>0.0000</td>
</tr>
<tr>
<td>2</td>
<td>PCT_RECT</td>
<td>-0.1398</td>
<td>-0.0996</td>
<td>-0.0630</td>
<td>0.0195</td>
<td>-5.1098</td>
<td>0.0000</td>
</tr>
<tr>
<td>3</td>
<td>MEAN_THICK_BRIDGE</td>
<td>0.0075</td>
<td>0.0189</td>
<td>0.0312</td>
<td>0.0060</td>
<td>3.1294</td>
<td>0.0018</td>
</tr>
<tr>
<td>4</td>
<td>NB_BRIDGE</td>
<td>0.1234</td>
<td>0.3480</td>
<td>0.5887</td>
<td>0.1182</td>
<td>2.9439</td>
<td>0.0032</td>
</tr>
<tr>
<td>5</td>
<td>PCT_RECT</td>
<td>0.0015</td>
<td>0.0159</td>
<td>0.0302</td>
<td>0.0073</td>
<td>2.1798</td>
<td>0.0293</td>
</tr>
</tbody>
</table>

Std. error: standard error; 95% confidence interval. Prob.: probability.
Cirrhosis prediction

[0223] The best BLR model includes 6 descriptors to predict cirrhosis (F4): PCT RECT, PCT NOD, AOF_STELLAR_EP, PCT GRANULARITY, DIST EP MEAN, and INDEX_FRAGMENTATION. As the logistic function (Figure 9) is not symmetric, there is no reason to use the a priori threshold of 0.5. Our rule was to maximize cirrhosis sensitivity since this is an important clinical diagnosis. In this model, the predictive threshold is selected “a posteriori” at 0.1567 providing a specificity of 0.964 and a sensitivity of 1. With this threshold, we correctly classified 96.6% of the patients and we obtain an AUROC of 0.994, thus showing an excellent model. Table 6 gives the overall results of performance for the original dataset (MALAH 1) and Table 6b provides the model coefficients.

Table 6. Overall results for the cirrhosis prediction model. Correct classification rate using an a posteriori 0.1567 threshold value. LWR and UPR: lower and upper bounds of the 5% confidence interval of the AUROC value.

<table>
<thead>
<tr>
<th>Population</th>
<th>Patients (n)</th>
<th>AUROC</th>
<th>Correctly classified (%)</th>
<th>Discordance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Value</td>
<td>LWR</td>
<td>UPR</td>
<td></td>
</tr>
<tr>
<td>MALAH 1</td>
<td>416</td>
<td>0.994</td>
<td>0.989</td>
<td>96.9</td>
</tr>
<tr>
<td>FIBROSYS W0</td>
<td>54</td>
<td>0.978</td>
<td>0.943</td>
<td>87.0</td>
</tr>
<tr>
<td>FIBROSYS W96</td>
<td>54</td>
<td>0.946</td>
<td>0.885</td>
<td>85.2</td>
</tr>
<tr>
<td>VINDIAG 10</td>
<td>83</td>
<td>0.968</td>
<td>0.928</td>
<td>91.6</td>
</tr>
</tbody>
</table>

Table 6b. Coefficients of the binary logistic regression for cirrhosis prediction.

<table>
<thead>
<tr>
<th>#</th>
<th>Variable</th>
<th>Lower</th>
<th>Coefficient</th>
<th>Upper</th>
<th>Std. Error</th>
<th>z-value</th>
<th>Prob.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PCT_RECT</td>
<td>-0.2318</td>
<td>-0.1304</td>
<td>-0.0438</td>
<td>0.0472</td>
<td>-2.7617</td>
<td>0.0058</td>
</tr>
<tr>
<td>2</td>
<td>PCT_NOD</td>
<td>0.0345</td>
<td>0.0808</td>
<td>0.1409</td>
<td>0.0271</td>
<td>2.9744</td>
<td>0.0029</td>
</tr>
<tr>
<td>3</td>
<td>AOF_STELLAR_EP</td>
<td>-4.9658</td>
<td>-3.2450</td>
<td>-1.9505</td>
<td>0.7590</td>
<td>-4.2751</td>
<td>0.0000</td>
</tr>
<tr>
<td>4</td>
<td>DIST_EP_MEAN</td>
<td>-11.5238</td>
<td>-6.0570</td>
<td>-1.6248</td>
<td>2.4783</td>
<td>-2.4440</td>
<td>0.0145</td>
</tr>
<tr>
<td>5</td>
<td>PCT_GRANULARITY</td>
<td>0.0461</td>
<td>0.0880</td>
<td>0.1432</td>
<td>0.0243</td>
<td>3.6275</td>
<td>0.0003</td>
</tr>
<tr>
<td>6</td>
<td>INDEX_FRAGMENTATION</td>
<td>0.0326</td>
<td>0.0732</td>
<td>0.1227</td>
<td>0.0226</td>
<td>3.2329</td>
<td>0.0012</td>
</tr>
</tbody>
</table>

Std. error: standard error; standard deviation. Prob.: probability
Lower: lower limit of 95% confidence interval.
Upper: upper limit of 95% confidence interval.

META VIR stage prediction

[0224] At the difference of the previously predictions (CSF and F4), we apply here a linear discriminant analysis (LDA) to predict the META VIR stages. The final model includes 8 descriptors: PCT GRANULARITY, PCT_RECT, PCT_NOD, RATIO_FPS, DF_FPS, DF_FPORT, RATIO_BRIDGE and INDEX_FRAGMENTATION. The LDA does not provide a unique META VIR score but it indicates a belonging probability for each stage. We use the classical method to affect a class by selecting the highest probability since the other imputations either (i) use arbitrary probability values or (ii) show no statistically better performance. The average discordance is of 0.315 and there is no patient with significant discordance (with a difference of 2 stages or more between META VIR stage and prediction according to the classical definition used with non-invasive tests of liver fibrosis). The results obtained (Figures 10 and 11) confirm that it is also a good model. Table 7 gives the overall results of performance for the original dataset (MALAH 1). Agreement between original Metavir stages and predicted stages was very good according to weighted kappa index = 0.868 (Table 7b). Tables 7c and 7d provides the model characteristics. Table 7e shows no significant discordance (≥ 2 F) between original and predicted stages.
**Table 7.** Overall results for the METAVIR stage prediction model. Discordance value using equal or proportional distances between METAVIR stages. Correct classification rate for all METAVIR or F4 stage(s).

<table>
<thead>
<tr>
<th>Population</th>
<th>Patients (n)</th>
<th>Discordance</th>
<th>Correctly classified (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Equal</td>
<td>Proportional</td>
</tr>
<tr>
<td>MALAH 1</td>
<td>416</td>
<td>0.315</td>
<td>0.315</td>
</tr>
<tr>
<td>FIBROSYS W0</td>
<td>54</td>
<td>0.407</td>
<td>0.407</td>
</tr>
<tr>
<td>FIBROSYS W96</td>
<td>54</td>
<td>0.463</td>
<td>0.500</td>
</tr>
<tr>
<td>VINDIAG 10</td>
<td>83</td>
<td>0.289</td>
<td>0.337</td>
</tr>
</tbody>
</table>

**Table 7b.** Overall agreement between the METAVIR stage and its prediction model.

<table>
<thead>
<tr>
<th>Kappa coefficient</th>
<th>lower</th>
<th>estimate</th>
<th>upper</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unweighted</td>
<td>0.493</td>
<td>0.555</td>
<td>0.618</td>
</tr>
<tr>
<td>Weighted</td>
<td>0.844</td>
<td>0.868</td>
<td>0.891</td>
</tr>
</tbody>
</table>

**Table 7c.** Prior probabilities used in the LDA model for the prediction of Metavir stages.

<table>
<thead>
<tr>
<th>F0</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
<th>F4</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0433</td>
<td>0.4062</td>
<td>0.2788</td>
<td>0.1418</td>
<td>0.1298</td>
</tr>
</tbody>
</table>

**Table 7d.** Coefficients of the LDA model for the prediction of Metavir stages.

<table>
<thead>
<tr>
<th>#</th>
<th>Variable</th>
<th>LD1</th>
<th>LD2</th>
<th>LD3</th>
<th>LD4</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PCT_GRAY</td>
<td>-0.0147</td>
<td>-0.0459</td>
<td>-0.0217</td>
<td>0.0406</td>
</tr>
<tr>
<td>2</td>
<td>PCT_RECT</td>
<td>0.0424</td>
<td>0.0039</td>
<td>0.0264</td>
<td>-0.0378</td>
</tr>
<tr>
<td>3</td>
<td>PCT_NOD</td>
<td>-0.0115</td>
<td>0.0019</td>
<td>-0.0063</td>
<td>-0.0055</td>
</tr>
<tr>
<td>4</td>
<td>RATIO_FPS</td>
<td>0.0479</td>
<td>-0.0340</td>
<td>-0.0219</td>
<td>0.0150</td>
</tr>
<tr>
<td>5</td>
<td>DF_FPS</td>
<td>-5.2464</td>
<td>8.9728</td>
<td>3.6717</td>
<td>1.7888</td>
</tr>
<tr>
<td>6</td>
<td>DF_FPORT</td>
<td>4.3518</td>
<td>-6.5818</td>
<td>-10.3962</td>
<td>-6.7348</td>
</tr>
<tr>
<td>7</td>
<td>RATIO_BRIDGE</td>
<td>-0.0181</td>
<td>-0.0005</td>
<td>0.0047</td>
<td>-0.0344</td>
</tr>
<tr>
<td>8</td>
<td>INDEX_FRAGMENTATION</td>
<td>-0.0107</td>
<td>-0.0244</td>
<td>0.0442</td>
<td>-0.0105</td>
</tr>
</tbody>
</table>

LDi is the coefficient of the ith discriminant function.

**Table 7e.** Distribution of original METAVIR stage and predicted stages.

<table>
<thead>
<tr>
<th>Metavir</th>
<th>Prediction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>F0</td>
</tr>
<tr>
<td>Original</td>
<td></td>
</tr>
<tr>
<td>F0</td>
<td>4</td>
</tr>
<tr>
<td>F1</td>
<td>6</td>
</tr>
<tr>
<td>F2</td>
<td>0</td>
</tr>
<tr>
<td>F3</td>
<td>0</td>
</tr>
<tr>
<td>F4</td>
<td>0</td>
</tr>
</tbody>
</table>
Validation populations

Model performance

[0225] Diagnostic accuracy of the diagnostic models based on automated morphometry was validated in Fibrosys and Vindiag 10 populations. Table 5 gives the overall results for CSF diagnosis in the three external validation datasets. Table 6 gives the overall results for cirrhosis diagnosis in the three external validation datasets. Table 7 gives the overall results for the Metavir stages in the three external validation datasets. Globally, there was an expected decrease in accuracy due to the lack of optimism bias. Nevertheless, the accuracies were still very good.

Application to clinical practice

[0226] In the Fibrostar population, the reference was Metavir staging performed by the central expert pathologist of Angers. The agreement between reference Metavir staging and second measurement was better with diagnosis by automated morphometry than initial diagnosis by local first line pathologist (Table 8).

Table 8. Agreement between reference diagnosis by central expert and diagnosis by automated morphometry method of the invention or local pathologist in the 285 patients of the Fibrostar population. For Metavir F stages we used three kinds of agreement index. As Fibrosis staging is an ordinal variable, weighted kappa or intra-class correlation coefficient should be preferred. Best values are in bold characters.

<table>
<thead>
<tr>
<th>Agreement of reference diagnosis with:</th>
<th>Morphometry</th>
<th>Local pathologist</th>
</tr>
</thead>
<tbody>
<tr>
<td>F stages:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- kappa</td>
<td>0.515</td>
<td>0.611</td>
</tr>
<tr>
<td>- weighted kappa</td>
<td>0.881</td>
<td>0.865</td>
</tr>
<tr>
<td>- intra-class correlation coefficient</td>
<td>0.934</td>
<td>0.929</td>
</tr>
<tr>
<td>CSF (kappa)</td>
<td>0.733</td>
<td>0.733</td>
</tr>
<tr>
<td>F4 (kappa)</td>
<td>0.900</td>
<td>0.827</td>
</tr>
</tbody>
</table>

Example 2: Reliability.

[0227] The accuracy of prediction is imperfect. These inaccurate results are not due to chance and can be predicted by statistical analysis providing significant independent predictors of accuracy. This defines the reliability analysis. Thus, one can calculate reliability classes where the accuracy varies and predictors can be different.

[0228] For example, a perfect result has 100% accuracy. A reliability analysis can determine reliability classes from 0 to 10, 20, 30, 40, 50, 60, 70, 80, 90% accuracy with specific predictors for each reliability class.

Predictors are issued from the list of descriptors of the invention.

[0229] For example, we provide here different predictive models obtained in different populations by binary logistic regression.

[0230] Tables of the coefficients of the binary logistic regression for prediction of accuracy for clinically significant fibrosis

Model # 1, AUROC = 0.656

<table>
<thead>
<tr>
<th>Variable</th>
<th>Lower</th>
<th>Coefficient</th>
<th>Upper</th>
<th>Std.error</th>
<th>z-value</th>
<th>Prob</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Intercept)</td>
<td>1.9388</td>
<td>4.2135</td>
<td>6.6344</td>
<td>1.1949</td>
<td>3.5263</td>
<td>0.0004</td>
</tr>
<tr>
<td>MEAN_THICK_BRIDGE</td>
<td>-0.0181</td>
<td>-0.0097</td>
<td>-0.0014</td>
<td>0.0042</td>
<td>-2.3029</td>
<td>0.0213</td>
</tr>
</tbody>
</table>
Tables of the coefficients of the binary logistic regression for prediction of accuracy for cirrhosis

Model # 1, AUROC = 0.916

<table>
<thead>
<tr>
<th>Variable</th>
<th>Lower</th>
<th>Coefficient</th>
<th>Upper</th>
<th>Std.error</th>
<th>z-value</th>
<th>Prob</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCT_NOD</td>
<td>-0.0719</td>
<td>-0.0369</td>
<td>-0.0061</td>
<td>0.0165</td>
<td>-2.2366</td>
<td>0.0253</td>
</tr>
</tbody>
</table>

Model # 2, AUROC = 0.959

<table>
<thead>
<tr>
<th>Variable</th>
<th>Lower</th>
<th>Coefficient</th>
<th>Upper</th>
<th>Std.error</th>
<th>z-value</th>
<th>Prob</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCT_NOD</td>
<td>-0.0924</td>
<td>-0.0550</td>
<td>-0.0232</td>
<td>0.0174</td>
<td>-3.1520</td>
<td>0.0016</td>
</tr>
<tr>
<td>PCT_RECT</td>
<td>0.0522</td>
<td>0.1474</td>
<td>0.2587</td>
<td>0.0518</td>
<td>2.8445</td>
<td>0.0044</td>
</tr>
<tr>
<td>N LENGTH</td>
<td>-0.2933</td>
<td>-0.1619</td>
<td>-0.0454</td>
<td>0.0618</td>
<td>-2.6220</td>
<td>0.0087</td>
</tr>
<tr>
<td>LB_LENGTH</td>
<td>0.2795</td>
<td>0.8925</td>
<td>1.6303</td>
<td>0.3404</td>
<td>2.6217</td>
<td>0.0087</td>
</tr>
<tr>
<td>DF_FPORT</td>
<td>4.2902</td>
<td>17.9175</td>
<td>33.1817</td>
<td>7.2281</td>
<td>2.4789</td>
<td>0.0132</td>
</tr>
</tbody>
</table>

Anfractuosity = ratio between the native perimeter and the smoothed perimeter of the liver

Model # 2, AUROC = 0.893

<table>
<thead>
<tr>
<th>Variable</th>
<th>Lower</th>
<th>Coefficient</th>
<th>Upper</th>
<th>Std.error</th>
<th>z-value</th>
<th>Prob</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEAN_AO_PORT</td>
<td>12.9522</td>
<td>47.5080</td>
<td>86.5260</td>
<td>18.6618</td>
<td>2.5457</td>
<td>0.0109</td>
</tr>
<tr>
<td>MEAN_PERIM_BRIDGE</td>
<td>-0.0012</td>
<td>-0.0006</td>
<td>-0.0001</td>
<td>0.0003</td>
<td>-2.4062</td>
<td>0.0161</td>
</tr>
<tr>
<td>RATIO_BRIDGE</td>
<td>-0.1333</td>
<td>-0.0714</td>
<td>-0.0106</td>
<td>0.0310</td>
<td>-2.3080</td>
<td>0.0210</td>
</tr>
<tr>
<td>PCT_NOD</td>
<td>-0.0558</td>
<td>-0.0296</td>
<td>-0.0051</td>
<td>0.0128</td>
<td>-2.3041</td>
<td>0.0212</td>
</tr>
<tr>
<td>AOF_BRIDGE</td>
<td>1.1042</td>
<td>4.8274</td>
<td>9.3013</td>
<td>2.0965</td>
<td>2.3026</td>
<td>0.0213</td>
</tr>
</tbody>
</table>

Model # 1, AUROC = 0.916

<table>
<thead>
<tr>
<th>Variable</th>
<th>Lower</th>
<th>Coefficient</th>
<th>Upper</th>
<th>Std.error</th>
<th>z-value</th>
<th>Prob</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCT_NOD</td>
<td>-0.0719</td>
<td>-0.0369</td>
<td>-0.0061</td>
<td>0.0165</td>
<td>-2.2366</td>
<td>0.0253</td>
</tr>
</tbody>
</table>

Model # 2, AUROC = 0.959

<table>
<thead>
<tr>
<th>Variable</th>
<th>Lower</th>
<th>Coefficient</th>
<th>Upper</th>
<th>Std.error</th>
<th>z-value</th>
<th>Prob</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCT_NOD</td>
<td>-0.0924</td>
<td>-0.0550</td>
<td>-0.0232</td>
<td>0.0174</td>
<td>-3.1520</td>
<td>0.0016</td>
</tr>
<tr>
<td>PCT_RECT</td>
<td>0.0522</td>
<td>0.1474</td>
<td>0.2587</td>
<td>0.0518</td>
<td>2.8445</td>
<td>0.0044</td>
</tr>
<tr>
<td>N LENGTH</td>
<td>-0.2933</td>
<td>-0.1619</td>
<td>-0.0454</td>
<td>0.0618</td>
<td>-2.6220</td>
<td>0.0087</td>
</tr>
<tr>
<td>LB_LENGTH</td>
<td>0.2795</td>
<td>0.8925</td>
<td>1.6303</td>
<td>0.3404</td>
<td>2.6217</td>
<td>0.0087</td>
</tr>
<tr>
<td>DF_FPORT</td>
<td>4.2902</td>
<td>17.9175</td>
<td>33.1817</td>
<td>7.2281</td>
<td>2.4789</td>
<td>0.0132</td>
</tr>
</tbody>
</table>
Example 3: Diagnosis of NASH.

Non-alcoholic fatty liver disease (NAFLD) is a frequent pathology. It encompasses the liver lesions linked to metabolic syndrome. It evolves from pure steatosis to non-alcoholic steato-hepatitis (NASH) and liver fibrosis. NASH includes several lesions: steatosis, hepatocyte ballooning, and lobular inflammation (Sanyal Hepatology 2011). An international expert team has described a NAFLD activity score (NAS) (Kleiner Hepatology 2005).

We have measured several lesions in a cohort of 235 patients with NAFLD. Optical microscopy included classical lesions (steatosis degree, NAS, NASH and fibrosis). Morphometry with image analysis included automatic measurement of area of steatosis (AOS) and fractal dimension of steatosis (DS) as well as area of fibrosis (AOF) and fractal dimension of fibrosis (DF). We also defined the relative Area of Steatosis (rAOS) as the area of steatosis in the non-fibrotic area.

Whatever the fibrosis stage, NAS was globally well correlated (p<0.001) with area of steatosis (AOS) (rs=0.746), relative Area of Steatosis (rAOS) (rs=0.761), and fractal dimension of steatosis (DS) (rs=0.794).

Mean fractal dimension of steatosis (DS) was much higher when NASH was present: 1.652±0.100 vs 1.395±0.126 in the absence of NASH (p=0.001).

Consequently, NASH was well predicted by relative Area of Steatosis (rAOS) with AUROC=0.919 with diagnostic accuracy at 85.6% or by fractal dimension of steatosis (DS): AUROC=0.936, diagnostic accuracy: 87.6%.

The best cut-off to diagnose NASH was relative Area of Steatosis (rAOS) =8.2% or fractal dimension of steatosis (DS)=1.595.

By stepwise binary logistic regression, NASH was diagnosed by the combination - called the NASH score - of fractal dimension of steatosis (DS), area of fibrosis (AOF) and relative Area of Steatosis (rAOS) with AUROC=0.953 and diagnostic accuracy= 87.6%. The proportion of patients with 95% predictive values for NASH was: rAOS: 44.6%, DS: 63.7%, NASH score: 75.5% (p<0.001 between each proportion by McNemar test).

Figure 12 shows the distribution of NASH diagnosis as a function of intervals of 95% predictive values by NASH score. The mean NASH scores of the patients were the following:

<table>
<thead>
<tr>
<th>NASH</th>
<th>Determination of the presence of NASH with the NASH score</th>
<th>Mean NASH score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>No</td>
<td>0.04</td>
</tr>
<tr>
<td></td>
<td>Doubtful</td>
<td>0.11</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>N/A</td>
</tr>
<tr>
<td>Indeterminate</td>
<td>No</td>
<td>0.43</td>
</tr>
<tr>
<td></td>
<td>Doubtful</td>
<td>0.47</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>0.55</td>
</tr>
<tr>
<td>Positive</td>
<td>No</td>
<td>0.88</td>
</tr>
<tr>
<td></td>
<td>Doubtful</td>
<td>0.93</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>0.97</td>
</tr>
</tbody>
</table>
Figure 13A shows the deciles of NASH score (X axis) plotted against the proportion of NASH diagnosis (Y axis). Figure 13B shows the box plots of NASH score as a function of 95% predictive values and NASH diagnosis. As shown in Figures 13A and B, with the 95% negative predictive value cut-off, there is no missed definitive NASH whereas with the 95% positive predictive value cut-off, there are only 3% of patients without NASH.

Moreover, we tested our descriptors in a new population of 137 patients with NAFLD. The histological definition of NASH was the most recent as described in a consensus paper (Sanyal Hepatology 2011). The NASH is defined as borderline or definitive diagnosis.

Results were the followings according to the two possible NASH definitions:

<table>
<thead>
<tr>
<th>NASH diagnostic target</th>
<th>Patient number (biopsy length)</th>
<th>AUROC</th>
<th>Correctly classified (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Borderline + definitive</td>
<td>107 (≥ 20 mm)</td>
<td>0.921</td>
<td>84.1</td>
</tr>
<tr>
<td></td>
<td>137 (all)</td>
<td>0.891</td>
<td>80.3</td>
</tr>
<tr>
<td>Definitive</td>
<td>107 (≥ 20 mm)</td>
<td>0.868</td>
<td>78.5</td>
</tr>
<tr>
<td></td>
<td>137 (all)</td>
<td>0.845</td>
<td>75.2</td>
</tr>
</tbody>
</table>

Model for definitive NASH

<table>
<thead>
<tr>
<th>Variable</th>
<th>Coefficient</th>
<th>Standard deviation</th>
<th>Z value</th>
<th>Probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contras_Fib Parenchyma</td>
<td>-0.05635018</td>
<td>0.022324528</td>
<td>-2.524137</td>
<td>1.159826e-02</td>
</tr>
<tr>
<td>Fractal dimension of steatosis</td>
<td>8.23338304</td>
<td>2.039900986</td>
<td>4.036168</td>
<td>5.433132e-05</td>
</tr>
<tr>
<td>Biopsy length</td>
<td>0.01743691</td>
<td>0.008354337</td>
<td>2.087169</td>
<td>3.687290e-02</td>
</tr>
<tr>
<td>AOF_STELLAR_TOT</td>
<td>14.95754878</td>
<td>3.578657393</td>
<td>4.179654</td>
<td>2.919533e-05</td>
</tr>
</tbody>
</table>

Model for borderline + definitive NASH

<table>
<thead>
<tr>
<th>Variable</th>
<th>Coefficient</th>
<th>Standard deviation</th>
<th>Z value</th>
<th>Probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constant</td>
<td>-17.43729686</td>
<td>4.05374381</td>
<td>-4.301529</td>
<td>1.696235e-05</td>
</tr>
<tr>
<td>Contras_Fib_Parenchyma</td>
<td>-0.09204421</td>
<td>0.03120528</td>
<td>-2.949636</td>
<td>3.181486e-03</td>
</tr>
<tr>
<td>Fractal dimension of steatosis</td>
<td>14.51277356</td>
<td>3.09510099</td>
<td>4.688950</td>
<td>2.746106e-06</td>
</tr>
<tr>
<td>AOF_STELLAR_EP</td>
<td>-0.40530236</td>
<td>0.20406950</td>
<td>-1.986100</td>
<td>4.702226e-02</td>
</tr>
<tr>
<td>AOF_STELLAR_TOT</td>
<td>15.77945921</td>
<td>4.22038919</td>
<td>3.738864</td>
<td>1.848540e-04</td>
</tr>
</tbody>
</table>

Example 4: Automatic measurement of lesions in a radiological image.

We developed image analysis from tomodensitometry (TDM) to allow an automated diagnosis of cirrhosis and other fibrosis stages. The advantage of the TDM images is that, contrary to a liver biopsy, we can evaluate the entire liver. Consequently, we dispose of more representative information. The way to proceed is the same as the liver biopsy method, except that we are not analysing one slice but several slices at intervals of 10 mm. Thus, for one patient we obtain approximately 15-20 images of 512 x 512 pixels with grey levels (Figure 14).

Semiaology

We can separate the measurements of descriptors in different categories (see Table 9):

<table>
<thead>
<tr>
<th>Category</th>
<th>Measurements</th>
</tr>
</thead>
<tbody>
<tr>
<td>External morphology</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>Anfractuosity:</td>
</tr>
</tbody>
</table>
As for the LB specimen, the analysis of the edges of the liver in TDM is an important descriptive factor to consider for the cirrhosis diagnosis. The edges tend to become more and more curved and irregular in the high fibrosis stages (Metavir F3, F4). The edges of spleen and liver may be assessed on a mask of the spleen and liver (Figure 15). Therefore, we measured the characteristic of anfractuosity with the *native perimeter of the liver* (mean and total perimeter).
perimeter), the smoothed perimeter of the liver (Figure 20) and the ratio between the native and smoothed perimeters. We also measured the largest perimeter among all the slices. The indentation of the liver can be interesting to evaluate the variation of the edges around smoothed edges. We completed the description of the liver external morphology with its height, the fractal dimension of its edges (Figure 18), the nodularity of its curved and irregular edges (Figure 16), and the angularity representing the angles present on the edges. We thus obtained a large number of variables describing the liver. Finally, we designed a box containing the liver wherein we measured the liver fat ratio (black pixels vs other pixels, Figure 17). We also calculated in the same manner the abdominal fat ratio (black pixels vs other pixels contained in the abdomen). We did the same evaluation for the spleen and we evaluated the spleen height, the total spleen perimeter, the ratio between the spleen area and the liver area and the nodularity of the spleen edges.

**Internal morphology (Figure 20)**

Other interesting parameters are the hypertrophy of liver segment I (one) which is observed in the high Metavir fibrosis stages, the width of the liver segment IV, and the ratio between segment I and segment IV dimensions. The hypertrophy is measured with different lengths (see Figure 19) and their mathematical combination (ratio and products). We used the inferior cave vein as a landmark for these measures: we obtained 2 antero-posterior lengths (D1 and D3, Figure 19A), 2 transversal lengths (D2 and D4, Figure 19A) and the surface of the segment I (Surf_S1, Figure 19B). The furrow thickness (D_F1) and surface (Surf_F1), especially the Arantius ligament which tends to increase in cirrhosis, were also evaluated (Figure 19C), as the the internal nodularity in the liver. The diameter of the portal vein was also measured.

**Structure**

We measured the heterogeneity of the density intensity in the image between several regions of interest (ROI) in the liver. Fractal organization of the hepatic parenchyma was also studied.

**Calculation**

The diagnostic value of radiological descriptors is calculated as follows.

The dependent variable is the diagnostic target among those of pathological liver lesions:

- Fibrosis as binary target like significant fibrosis or cirrhosis or staging like Metavir staging.
- Steatosis.

The independent variables are selected among the list of available radiological descriptors among those known in the literature plus the new signs described in the present application.

The dependent variable is predicted by the independent variables thanks to appropriate statistical multivariate analysis like binary logistic regression or discriminant analysis. The multivariate analysis provides a score including one to several independent variables.

**Example:**

Population: 30 patients with chronic hepatitis C, liver biopsy (Metavir staging) and TDM.

<table>
<thead>
<tr>
<th>Diagnostic target</th>
<th>Significant fibrosis</th>
<th>Cirrhosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUROC</td>
<td>0.882</td>
<td>0.893</td>
</tr>
<tr>
<td>Correctly classified (%)</td>
<td>79.3</td>
<td>75.9</td>
</tr>
<tr>
<td>Score coefficients:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constant</td>
<td>-1.148</td>
<td>-2.645</td>
</tr>
<tr>
<td>Furrow surface</td>
<td>2.793</td>
<td>2.026</td>
</tr>
<tr>
<td>P value for furrow surface</td>
<td>0.031</td>
<td>0.005</td>
</tr>
</tbody>
</table>
Claims

1. A method for assessing the presence and/or the severity of a lesion in an organ or tissue of a subject through automated analysis of at least one image of said organ or tissue, wherein said organ or tissue is preferably a liver organ or liver tissue, comprising the calculation of a score combining descriptors of said image, wherein said method comprises the steps of:

   a. measuring on said at least one image at least two, descriptors of said at least one image;
   b. mathematically combining said at least two descriptors in a score; and
   c. assessing the presence and/or the severity of a lesion in the organ or tissue based on the value of the score calculated at step (b).

2. The method according to claim 1, wherein said method is computerized.

3. The method according to claim 1 or claim 2, wherein the at least two descriptors are selected from the list comprising fractal dimension of the edges of the organ or fragment thereof, linearity percentage of the edges, nodularity of the curved and irregular edges of the organ, angularity, length of the organ or fragment thereof, length of a biopsy, such as, for example, length of a liver biopsy, length of numeric specimen, height of the organ, perimeter of the organ or fragment thereof, mean and total native perimeter of the organ, smoothed perimeter of the organ, ratio between the native and smoothed perimeters, largest perimeter of the organ, indentation of the organ, area of the organ or fragment thereof, granularity percentage, fragmentation, mean intensity of the image on the red component, mean intensity of the image on the green component, mean intensity of the image on the blue component, area of fibrosis, fractal dimension of fibrosis, mean of percentage of fibrosis around areas, number of nodules, number of nodules with more than 30% of fibrosis around, area of steatosis, relative area of steatosis, fractal dimension of steatosis, area of portal-septal fibrosis, fractal dimension of portal-septal fibrosis, area of peri-sinusoidal fibrosis, fractal dimension of peri-sinusoidal fibrosis, area of lobular peri-sinusoidal fibrosis, ratio of peri-sinusoidal fibrosis among the whole fibrosis, luminosity of fibrosis staining in the red, green and/or blue components, luminosity of the parenchyma staining in the red, green and/or blue components, luminosity contrast between fibrosis and parenchyma, luminosity contrast between fibrosis and the organ or fragment thereof, area of stellar fibrosis among the total surface of the LB specimen, area of stellar fibrosis among the surface of portal-septal regions, area of stellar fibrosis among the surface of lobular regions, number of portal-septal regions, mean area of stellar fibrosis, mean area of portal-septal regions, number of bridges, ratio of bridges among the portal-septal areas, area of fibrosis in the bridges, bridges thickness, bridges perimeter, bridges surface, portal distance, organ fat ratio, abdominal fat ratio, hypertrophy of liver segment I, surface of the segment I, width of the liver segment IV, ratio between segment I and segment IV dimensions, furrow thickness, surface of the furrow I, internal nodularity in the liver, diameter of the portal vein, heterogeneity of the density intensity, fractal organization of the organ.

4. The method according to anyone of claims 1 to 3, wherein the at least one image is a histological section image, more preferably an image of a histological section from a biopsy sample of said organ or tissue; or an image of the entire organ or tissue, more preferably said image is non-invasively recovered from a living organism.

5. The method according to anyone of claims 1 to 4, comprising recovering

   - at least one histological section image, more preferably an image of a histological section from a biopsy sample of said organ or tissue; and
   - at least one image of the entire organ or tissue, more preferably said image is non-invasively recovered from a living organism.

6. The method according to anyone of claims 1 to 5, wherein the at least one image is obtained by an optical technique, preferably microscopic physical imaging, such as, for example electron microscopy, second harmonic generation (SHG), multiphoton imaging, coherent anti-Stokes Raman scattering - CARS), two-photon excitation fluorescence (TPEF), diffuse optical imaging or event-related optical signal.

7. The method according to anyone of claims 1 to 6, wherein the at least one image is obtained by a non-optical technique, preferably selected from the group comprising radiography, such as, for example, X-ray, ultrasonography, computerized scanner, magnetic resonance imaging (MRI), functional magnetic resonance imaging, tomography, computed axial tomography, proton emission tomography (PET) or single photon emission computed tomography; and nuclear medicine, such as, for example, scintigraphy; photoacoustic methods; thermal methods; and manne-
toencephalography.

8. The method according to anyone of claims 1 to 7, wherein the mathematical combination is a combination using a mathematical function, preferably a multivariate analysis, more preferably a multivariate analysis selected from the list comprising binary logistic regression, linear discriminant analysis or multivariate analysis.

9. The method according to anyone of claims 1 to 8, wherein the lesion is a fibrosis.

10. The method according to anyone of claims 1 to 9, wherein the organ or tissue is selected from the list comprising liver, skin, heart, lung, kidney, gut, intestine, pancreas, bone marrow, muscle, joints and soft tissue such as, for example, soft tissue of the mediastinum or soft tissue of the retroperitoneum.

11. The method according to anyone of claims 1 to 10, wherein the lesion is a liver fibrosis, preferably a portal fibrosis or a peri-sinusoidal fibrosis.

12. The method according to anyone of claims 1 to 11, wherein the score obtained in step (c) is a diagnostic score indicative of the presence and/or of the severity of a disease, preferably of cirrhosis or of clinically significant fibrosis, more preferably of clinically significant fibrosis.

13. The method according to anyone of claims 1 to 12, wherein the score obtained in step (c) is a diagnostic score indicative of the presence and/or of the severity of NASH, preferably definitive or borderline and definitive NASH.

14. The method according to anyone of claims 1 to 13, wherein the score obtained in step (c) is a prognostic score, preferably is indicative of an increased risk of mortality or of liver mortality or of hepatic complications.

15. The method according to anyone of claims 1 to 14, further comprising measuring at least one non-invasive test marker, and optionally mathematically combining said at least one non-invasive test marker with the at least two descriptors in a score.

16. A descriptor selected from the group comprising fractal dimension of the edges of the organ or fragment thereof, linearity percentage of the edges, nodularity of the curved and irregular edges of the organ, angularity, length of the organ or fragment thereof, length of a biopsy, such as, for example, length of a liver biopsy, length of numeric specimen (N_LENGTH), height of the organ, perimeter of the organ or fragment thereof, mean and total native perimeter of the organ, smoothed perimeter of the organ, ratio between the native and smoothed perimeters, largest perimeter of the organ, indentation of the organ, area of the organ or fragment thereof, granularity percentage, fragmentation, mean intensity of the image on the red component, mean intensity of the image on the green component, mean intensity of the image on the blue component, area of fibrosis, fractal dimension of fibrosis, mean of percentage of fibrosis around areas, number of nodules, number of nodules with more than 30% of fibrosis around, area of steatosis, relative area of steatosis, fractal dimension of steatosis, area of porto-septal fibrosis, fractal dimension of porto-septal fibrosis, area of peri-sinusoidal fibrosis, fractal dimension of peri-sinusoidal fibrosis, area of lobular peri-sinusoidal fibrosis, ratio of peri-sinusoidal fibrosis among the whole fibrosis, luminosity of fibrosis staining in the red, green and/or blue components, luminosity of the parenchyma staining in the red, green and/or blue components, luminosity contrast between fibrosis and parenchyma, luminosity contrast between fibrosis and the organ or fragment thereof, area of stellar fibrosis among the total surface of the LB specimen, area of stellar fibrosis among the surface of porto-septal regions, area of stellar fibrosis among the surface of lobular regions, number of porto-septal regions; mean area of stellar fibrosis, mean area of porto-septal regions, number of bridges, ratio of bridges among the porto-septal areas, area of fibrosis in the bridges, bridges thickness, bridges perimeter, bridges surface, portal distance, organ fat ratio, abdominal fat ratio, hypertrophy of liver segment I, surface of the segment I, width of the liver segment IV, ratio between segment I and segment IV dimensions, furrow thickness, surface of the furrow I, internal nodularity in the liver, diameter of the portal vein, heterogeneity of the density intensity, fractal organization of the organ.
Distribution of the CSF prediction as a function of METAVIR staging

- density (smoothed)
- median
- values
- overall median

a priori threshold 0.5

FIG. 8
Distribution of the logistic function for the F4 prediction

- ▲ original F4 value
- ○ original non-F4 value
- ★ severe misclassification

A priori 0.500
Max.Acc. 0.246
Youden 0.1567 (a posteriori)

FIG. 9
Distribution of the META VIR stage prediction

FIG. 10
Agreement between prediction of METAVIR stages and evaluation by an expert

Expert evaluation of METAVIR stages

FIG. 11
Mean NASH score: .04 .11 .43 .47 .55 .88 .93 .97

95% predictive values of NASH score for NASH

FIG. 12
**FIG. 13**
FIG. 20
# EUROPEAN SEARCH REPORT

**Application Number**
EP 13 15 7488

**DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IPC)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>* page 1, line 4 - line 10 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 4, line 14 - line 19 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 5 - page 6 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 17, line 15 - line 22 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 20, line 18 - line 24 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 21, line 5 - line 29 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 31, line 1 - line 9 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-----</td>
<td></td>
<td></td>
</tr>
<tr>
<td>X</td>
<td>WO 2011/123068 A1 (AGENCY FOR SCIENCES TECHNOLOGY AND RES [SG]; YU HANRY [SG]; TAI DEAN [ ]) 6 October 2011 (2011-10-06) * abstract *</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>* figure 1 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* tables 1,3 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 1, line 5 - line 10 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 5, line 30 - page 6, line 22 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 18, line 20 - page 21, line 10 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 24, line 5 - line 32 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-----</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* tables 1,2 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 1, line 4 - line 22 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 15, line 9 - page 21, line 19 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 31, line 6 - page 32, line 15 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-----</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The present search report has been drawn up for all claims

**Place of search**
Munich

**Date of completion of the search**
4 June 2013

**Examiner**
Scholz, Volker

**CATEGORY OF CITED DOCUMENTS**

- **X**: particularly relevant if taken alone
- **Y**: particularly relevant if combined with another document of the same category
- **A**: Technological background
- **P**: Intermediate document
- **T**: Theory or principle underlying the invention
- **E**: Earlier patent document, but published on, or after the filing date
- **D**: Document cited in the application
- **L**: Document cited for other reasons
- **a**: Member of the same patent family, corresponding document
This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on 04/06/2013. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>US 2011313276 A1</td>
<td>22-12-2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2010058295 A2</td>
<td>27-05-2010</td>
</tr>
<tr>
<td>WO 2011123068 A1</td>
<td>06-10-2011</td>
<td>SG 184389 A1</td>
<td>30-10-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2013030305 A1</td>
<td>31-01-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2011123068 A1</td>
<td>06-10-2011</td>
</tr>
<tr>
<td>WO 2007140814 A1</td>
<td>13-12-2007</td>
<td>AT 474292 T</td>
<td>15-07-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2006344283 A1</td>
<td>13-12-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2652658 A1</td>
<td>13-12-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 101460976 A</td>
<td>17-06-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2024933 A1</td>
<td>18-02-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2009540272 A</td>
<td>19-11-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009232382 A1</td>
<td>17-09-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2007140814 A1</td>
<td>13-12-2007</td>
</tr>
</tbody>
</table>

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82.
REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 2012226709 A [0009]

Non-patent literature cited in the description